<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ibuprofen: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ibuprofen: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ibuprofen: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11763" href="/d/html/11763.html" rel="external">see "Ibuprofen: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13371" href="/d/html/13371.html" rel="external">see "Ibuprofen: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708913"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiovascular thrombotic events (excluding NeoProfen):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious gastrointestinal bleeding, ulcerations, and perforation (excluding NeoProfen):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI  bleeding are at greater risk for serious GI events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181456"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Addaprin [OTC] [DSC];</li>
<li>Advil Junior Strength [OTC];</li>
<li>Advil Liqui-Gels minis [OTC];</li>
<li>Advil Migraine [OTC];</li>
<li>Advil [OTC];</li>
<li>Caldolor;</li>
<li>Childrens Advil [OTC];</li>
<li>Childrens Ibuprofen [OTC] [DSC];</li>
<li>Childrens Motrin [OTC];</li>
<li>Dyspel [OTC] [DSC];</li>
<li>FT Ibuprofen Childrens [OTC];</li>
<li>FT Ibuprofen IB Childrens [OTC];</li>
<li>FT Ibuprofen Minis [OTC];</li>
<li>FT Ibuprofen [OTC];</li>
<li>GoodSense Ibuprofen Childrens [OTC];</li>
<li>GoodSense Ibuprofen [OTC];</li>
<li>I-Prin [OTC] [DSC];</li>
<li>IBU;</li>
<li>IBU-200 [OTC];</li>
<li>Ibuprofen Childrens [OTC];</li>
<li>Infants Advil [OTC];</li>
<li>KS Ibuprofen [OTC] [DSC];</li>
<li>Medi-First Ibuprofen [OTC];</li>
<li>Motrin Childrens [OTC];</li>
<li>Motrin IB [OTC];</li>
<li>Motrin Infants Drops [OTC];</li>
<li>NeoProfen;</li>
<li>Provil [OTC] [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867160"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Ibuprofen;</li>
<li>Caldolor [DSC];</li>
<li>PMS-Ibuprofen [DSC];</li>
<li>TEVA-Profen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181507"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Nonopioid;</li>
<li>
                        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;</li>
<li>
                        Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral</li></ul></div>
<div class="block doa drugH1Div" id="F181461"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis. Consider proton pump inhibitor coadministration in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-19017521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-19017521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use the lowest effective dose for the shortest duration of time.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aa64061-6e3a-4e32-801e-0989bd1fbc53">Abnormal uterine bleeding, nonacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, nonacute (alternative agent) (off-label use): Note: </b>Not indicated for management of acute abnormal bleeding (ie, excessively heavy or prolonged bleeding that requires urgent evaluation). Alternative for patients who cannot or choose not to use hormonal therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>). Dosing based on limited data and expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>600 mg 2 to 4 times daily. Begin at menses onset and continue for 2 to 3 days or until cessation of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1','lexi-content-ref-3533137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1','lexi-content-ref-3533137'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="462a3a59-e36e-4308-9661-36c83a515c19">Anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory (eg, for arthritis associated with rheumatic disease): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 to 800 mg every 6 to 8 hours; maximum dose: 3.2 g/day. Some experts generally recommend a maximum dose of 2.4 g/day for chronic use, except during a disease flare when up to 3.2 g/day may be considered for several weeks until flare resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Solomon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Solomon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a95f7bf7-e7b2-4183-a9d6-2ca350b1202b">Dysmenorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysmenorrhea:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 400 mg every 4 hours as needed or 600 to 800 mg every 6 to 8 hours as needed; maximum dose: 3.2 g/day. Begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; usual duration: 1 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26224322','lexi-content-ref-Smith.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26224322','lexi-content-ref-Smith.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="329ed298-f3e6-444f-90c2-4d78bdfdcf71">Fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fever (alternative agent):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 200 to 400 mg every 4 to 6 hours as needed; if fever persists, may titrate up to 600 to 800 mg every 6 hours as needed; maximum dose: 3.2 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21127424','lexi-content-ref-19949916','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21127424','lexi-content-ref-19949916','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling (patient-guided therapy</i>):<b> Oral:</b> 200 mg every 4 to 6 hours as needed; if no relief, may increase to 400 mg every 4 to 6 hours as needed; maximum dose: 1.2 g/day. Use for &gt;3 days is not recommended unless directed by health care provider.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 800 mg every 8 hours within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1','lexi-content-ref-579229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1','lexi-content-ref-579229'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94e2a3ee-a6a7-47a4-9a9e-1102ebb9cf5e">Migraine, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limit use to ≤14 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>). For use as monotherapy in mild to moderate attacks not associated with vomiting or severe nausea; may be used in combination with triptans for severe migraine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27322907','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27322907','lexi-content-ref-Schwedt.1'])">Ref</a></span>). Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 to 600 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23968886','lexi-content-ref-23633348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23968886','lexi-content-ref-23633348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling (patient-guided therapy):</i>
<b>Oral:</b> 400 mg at onset of symptoms.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="10e80117-63f7-43fa-95c9-0c85ee3d6a40">Pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain (monotherapy or as an adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 200 to 400 mg every 4 to 6 hours as needed or 600 to 800 mg every 6 to 8 hours as needed; maximum dose: 3.2 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-19588326','lexi-content-ref-18253976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-19588326','lexi-content-ref-18253976'])">Ref</a></span>). For postoperative pain, doses may be scheduled initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwenk.1'])">Ref</a></span>). Some experts suggest a usual maximum of 2.4 g/day for chronic use due to increased adverse effects with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Knight.1','lexi-content-ref-Pandharipande.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Knight.1','lexi-content-ref-Pandharipande.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling (patient-guided therapy):</i>
<b>Oral:</b> 200 mg every 4 to 6 hours as needed; if no relief, may increase to 400 mg every 4 to 6 hours as needed; maximum dose: 1.2 g/day. Use for &gt;10 days is not recommended unless directed by health care provider.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="236d546c-b735-4016-861b-18e58e48239e">Pericarditis, acute or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pericarditis, acute or recurrent (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with an indication for aspirin (eg, coronary artery disease), aspirin is generally preferred over other nonsteroidal anti-inflammatory drugs (NSAIDs). Avoid nonaspirin NSAIDs in patients with pericarditis secondary to acute myocardial infarction given lack of benefit and potential harm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-26320112','lexi-content-ref-LeWinter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-26320112','lexi-content-ref-LeWinter.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 600 to 800 mg every 8 hours or 600 mg every 6 hours until resolution of symptoms for at least 24 hours and normalization of inflammatory biomarkers (eg, C-reactive protein) if monitored; initial therapy typically lasts for ≥1 to 2 weeks. Gradually taper over several weeks by decreasing each dose by 200 to 400 mg every 1 to 2 weeks; during taper, ensure patient remains asymptomatic and inflammatory biomarkers remain normal (if monitored). Use in combination with colchicine. In patients at risk of NSAID-related GI toxicity, prophylaxis (generally with a proton pump inhibitor) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320112','lexi-content-ref-Imazio.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320112','lexi-content-ref-Imazio.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990814"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV, Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3958223','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3958223','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;30 to &lt;60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3958223','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3958223','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use of analgesics other than nonsteroidal anti-inflammatory drugs may be preferred. If necessary, use the lowest effective dose for the shortest duration possible; avoid in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤ 30 mL/minute: Avoid use due to increased risk of acute kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3958223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3958223'])">Ref</a></span>): No dosage adjustment necessary. Avoid use in patients with residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary. Avoid use in patients with residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988019"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution to avoid adverse effects and discontinue if hepatic function worsens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F181462"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Consider reduced initial dosage. Unless alternative agents are ineffective and a gastroprotective agent can be administered, avoid short-term scheduled use in combination with corticosteroids, anticoagulants, or antiplatelet agents or chronic use with or without medications that increase risk for bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F181483"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13371" href="/d/html/13371.html" rel="external">see "Ibuprofen: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time to achieve treatment goals.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Oral liquid products are available in 2 concentrations (concentrated infant drops: 50 mg/1.25 mL [40 mg/mL] and suspension: 100 mg/5 mL [20 mg/mL]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg".</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c6ec689-e9af-41ae-8ca3-0221147a37b3">Analgesic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: Ibuprofen injection (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months to &lt;6 months: IV: 10 mg/kg/dose as a single dose; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;12 years: IV: 10 mg/kg/dose (maximum dose: 400 mg/dose) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents ≤17 years: IV: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: 400 to 800 mg every 6 hours as needed; maximum daily dose: 3,200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Infants, Children, and Adolescents: Limited data available in infants &lt;6 months: Oral: 4 to 10 mg/kg/dose (maximum dose: 600 mg/dose) every 6 to 8 hours; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2216644','lexi-content-ref-12362012','lexi-content-ref-25011346','lexi-content-ref-Zeltzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2216644','lexi-content-ref-12362012','lexi-content-ref-25011346','lexi-content-ref-Zeltzer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children ≤11 years: Oral: See table based upon manufacturer's labeling; use of weight to select dose is preferred; if weight is not available, then use age; doses may be repeated every 6 to 8 hours; maximum: 4 doses/<b>day</b>; treatment of sore throat for &gt;2 days or use in infants and children &lt;3 years of age with sore throat is not recommended, unless directed by health care provider.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ibuprofen Dosing</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="2">
<p style="text-indent:0em;">Weight (preferred)<sup>a</sup></p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Age</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Dosage</p>
<p style="text-indent:0em;">(mg)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">kg</p></th>
<th align="center">
<p style="text-indent:0em;">lbs</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">5.4 to 8.1</p></td>
<td align="center">
<p style="text-indent:0em;">12 to 17</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 11 months</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8.2 to 10.8</p></td>
<td align="center">
<p style="text-indent:0em;">18 to 23</p></td>
<td align="center">
<p style="text-indent:0em;">12 to 23 months</p></td>
<td align="center">
<p style="text-indent:0em;">75 to 80</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10.9 to 16.3</p></td>
<td align="center">
<p style="text-indent:0em;">24 to 35</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 years</p></td>
<td align="center">
<p style="text-indent:0em;">100</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16.4 to 21.7</p></td>
<td align="center">
<p style="text-indent:0em;">36 to 47</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 5 years</p></td>
<td align="center">
<p style="text-indent:0em;">150</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">21.8 to 27.2</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 59</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 8 years</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">27.3 to 32.6</p></td>
<td align="center">
<p style="text-indent:0em;">60 to 71</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 10 years</p></td>
<td align="center">
<p style="text-indent:0em;">200 to 250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32.7 to 43.2</p></td>
<td align="center">
<p style="text-indent:0em;">72 to 95</p></td>
<td align="center">
<p style="text-indent:0em;">11 years</p></td>
<td align="center">
<p style="text-indent:0em;">300</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Manufacturer's recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 200 to 400 mg every 4 to 6 hours as needed; treatment of pain for &gt;10 days is not recommended, unless directed by health care provider (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8bb947be-8aac-45a0-a7ca-03bb9e4fd9b7">Antipyretic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antipyretic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: Ibuprofen injection (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months to &lt;6 months: IV: 10 mg/kg/dose as a single dose; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;12 years: IV: 10 mg/kg/dose (maximum dose: 400 mg/dose) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents ≤17 years: IV: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: Initial dose: 400 mg once, followed by 400 mg every 4 to 6 hours <b>or </b>100 to 200 mg every 4 hours as needed; maximum daily dose: 3,200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Infants ≥3 months weighing ≥5 kg, Children, and Adolescents: Limited data available in infants &lt;6 months: Oral: 5 to 10 mg/kg/dose (maximum dose: 600 mg/dose) every 6 to 8 hours; maximum daily dose: 40 mg/kg/<b>day</b> or 2,400 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28760789','lexi-content-ref-2279802','lexi-content-ref-1447669','lexi-content-ref-7884951','lexi-content-ref-10506264','lexi-content-ref-11735667','lexi-content-ref-8660083','lexi-content-ref-Nield.1','lexi-content-ref-935827','lexi-content-ref-21357332','lexi-content-ref-28516288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28760789','lexi-content-ref-2279802','lexi-content-ref-1447669','lexi-content-ref-7884951','lexi-content-ref-10506264','lexi-content-ref-11735667','lexi-content-ref-8660083','lexi-content-ref-Nield.1','lexi-content-ref-935827','lexi-content-ref-21357332','lexi-content-ref-28516288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: <b>Note:</b> Treatment for &gt;3 days is not recommended unless directed by health care provider.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children ≤11 years: Oral: See table based upon manufacturer's labeling; use of weight to select dose is preferred; if weight is not available, then use age; doses may be repeated every 6 to 8 hours; maximum: 4 doses/<b>day</b>.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Ibuprofen Dosing</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="2">
<p style="text-indent:0em;">Weight (preferred)<sup>a</sup></p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Age</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Dosage</p>
<p style="text-indent:0em;">(mg)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">kg</p></th>
<th align="center">
<p style="text-indent:0em;">lbs</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">5.4 to 8.1</p></td>
<td align="center">
<p style="text-indent:0em;">12 to 17</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 11 months</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8.2 to 10.8</p></td>
<td align="center">
<p style="text-indent:0em;">18 to 23</p></td>
<td align="center">
<p style="text-indent:0em;">12 to 23 months</p></td>
<td align="center">
<p style="text-indent:0em;">75 to 80</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10.9 to 16.3</p></td>
<td align="center">
<p style="text-indent:0em;">24 to 35</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 years</p></td>
<td align="center">
<p style="text-indent:0em;">100</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16.4 to 21.7</p></td>
<td align="center">
<p style="text-indent:0em;">36 to 47</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 5 years</p></td>
<td align="center">
<p style="text-indent:0em;">150</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">21.8 to 27.2</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 59</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 8 years</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">27.3 to 32.6</p></td>
<td align="center">
<p style="text-indent:0em;">60 to 71</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 10 years</p></td>
<td align="center">
<p style="text-indent:0em;">200 to 250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32.7 to 43.2</p></td>
<td align="center">
<p style="text-indent:0em;">72 to 95</p></td>
<td align="center">
<p style="text-indent:0em;">11 years</p></td>
<td align="center">
<p style="text-indent:0em;">300</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a </sup>Manufacturer's recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 200 to 400 mg every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c1b2aef-7dbb-4a04-a8a0-8ff1ce1fc509">Cystic fibrosis, mild disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, mild disease (to slow lung disease progression): </b> Limited data available: Children and Adolescents 6 to 17 years with FEV<sub>1</sub> &gt;60% predicted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878'])">Ref</a></span>): Oral: Initial: 20 to 30 mg/kg/dose twice daily; titrate to achieve peak plasma concentrations of 50 to 100 mcg/mL; should not eat or take pancreatic enzymes for 2 hours after the ibuprofen dose. Dosing based on a study of 41 patients (ages: 5 to 39 years); mean required dose: ~25 mg/kg/dose twice daily; reported range: 16.2 to 31.6 mg/kg/dose every 12 hours required to achieve target concentration; results showed that chronic ibuprofen use (over 4 years) slowed the rate of decline in FEV<sub>1</sub>; patients 5 to 13 years of age with mild lung disease were observed to have greatest benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7503838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7503838'])">Ref</a></span>). A follow up observational study (n=1,365; ages: 6 to 17 years) under noncontrolled conditions (real world) showed significant improvement in the rate of decline of lung disease progression with chronic ibuprofen therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17872492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17872492'])">Ref</a></span>). <b>Note:</b> Timing of blood sampling postdose is based on dosage form: Oral suspension: Obtain blood samples at 30, 45, and 60 minutes postdose; tablets: Obtain blood samples at 1, 2, and 3 hours postdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11735667','lexi-content-ref-Scott.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11735667','lexi-content-ref-Scott.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA):</b> Children and Adolescents: Oral: Usual range: 30 to 40 mg/kg/day in 3 to 4 divided doses; start at lower end of dosing range and titrate; patients with more severe disease may require up to 50 mg/kg/<b>day</b>; maximum dose: 800 mg/dose; maximum daily dose: 2,400 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2213396','lexi-content-ref-21218015','lexi-content-ref-11735667','lexi-content-ref-Petty.1','lexi-content-ref-Wu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2213396','lexi-content-ref-21218015','lexi-content-ref-11735667','lexi-content-ref-Petty.1','lexi-content-ref-Wu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113401"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Oral, IV (Caldolor): There are no dosage adjustments provided in the manufacturer's labeling; avoid use in advanced disease.</p>
<p style="text-indent:-2em;margin-left:4em;">KDIGO guidelines provide the following recommendations for NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Avoid use in patients with intercurrent disease that increases risk of acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F51113402"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution and discontinue if hepatic function worsens.</p></div>
<div class="block arsc drugH1Div" id="F56437604"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including <b>acute myocardial infarction</b> (MI), <b>cerebrovascular accident</b>, and CV death. New-onset <b>hypertension</b> or <b>exacerbation of hypertension</b> may occur with NSAID use which may also contribute to an increased risk of CV events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020251'])">Ref</a></span>). New-onset or exacerbation of <b>heart failure</b> may also occur with cyclooxygenase (COX) NSAIDs (ie, coxibs) and nonselective NSAIDs, including ibuprofen, resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data collected by the Coxib and traditional NSAID Trialists’ (CNT) Collaborative have shown that high-dose ibuprofen (2,400 mg daily) and diclofenac are associated with a similar CV risk as compared to coxibs and that naproxen may have the most favorable CV risk profile among NSAIDs analyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390'])">Ref</a></span>); however, data from the PRECISION trial showed no difference with regards to risk between naproxen, ibuprofen, or celecoxib after a treatment duration of therapy of ~3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959716'])">Ref</a></span>). The FDA states that there are insufficient data to determine if risk of MI or stroke is definitely higher or lower for any particular NSAID as compared to another (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I<sub>2</sub> (prostacyclin) in the vascular endothelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11509629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11509629'])">Ref</a></span>); animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964481'])">Ref</a></span>). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increased risk may be apparent within the first weeks following initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-21555710'])">Ref</a></span>); longer duration of therapy may further increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (especially with regards to CV thrombotic risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use and frequent use (eg, ≥22 days per month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16534006','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16534006','lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (CVD) or presence of risk factors for CVD, including use following coronary artery bypass graft surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note: </b>Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially nonselective NSAIDs, such as ibuprofen, is associated with an increased risk of serious GI adverse events, including <b>gastrointestinal</b>
<b>inflammation</b>, <b>gastrointestinal hemorrhage</b>, <b>gastrointestinal</b>
<b>ulcer</b>, and <b>gastrointestinal</b>
<b>perforation</b>; severity may range from asymptomatic to fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of cyclooxygenase (COX)-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E<sub>2 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626023','lexi-content-ref-10377455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626023','lexi-content-ref-10377455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; GI events can occur at any time during use and without warning symptoms. A longer duration of use (eg, ≥7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33238721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33238721'])">Ref</a></span>)) is associated with a greater risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (eg, ≥7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33238721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33238721'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909103'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of peptic ulcer disease and/or GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>), anticoagulants, corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-2012355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-2012355'])">Ref</a></span>), selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid <i>Helicobacter pylori </i>infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16469671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16469671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced liver disease/cirrhosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">• Consumption of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• People with poor general health status</p>
<p style="text-indent:-2em;margin-left:6em;">• Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052268'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, is associated with <b>prolonged bleeding time</b> and an increased risk for<b> hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18359332','lexi-content-ref-25402512','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18359332','lexi-content-ref-25402512','lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In addition, drug-induced <b>hemolytic anemia</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25247621','lexi-content-ref-3545733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25247621','lexi-content-ref-3545733'])">Ref</a></span>). Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, <b>agranulocytosis</b>, <b>aplastic anemia</b>, <b>neutropenia</b>, <b>thrombocytopenia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33100559','lexi-content-ref-8379803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33100559','lexi-content-ref-8379803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Inhibition of cyclooxygenase (COX)-1 by nonselective NSAIDs causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A<sub>2</sub> (TxA<sub>2</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2724096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2724096'])">Ref</a></span>). As a result, patients may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Blood dyscrasias: Not clearly established; anemia may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332'])">Ref</a></span>). In patients receiving antithrombotic therapy after myocardial infarction, the use of NSAIDs has been associated with an increased risk of bleeding and excess thrombotic events, even after short-term treatment (eg, &lt;3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bleeding events:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting coagulation disorders</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668365','lexi-content-ref-24733305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668365','lexi-content-ref-24733305'])">Ref</a></span>), antithrombotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>), antiplatelet agents [eg, aspirin], selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>), or serotonin norepinephrine reuptake inhibitors)</p>
<p style="text-indent:-2em;margin-left:8em;">- Use during and immediately following surgical procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15809462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15809462'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, may cause mild transaminase elevations, especially with higher doses. Rarely, serious liver injury may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794','lexi-content-ref-30112779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794','lexi-content-ref-30112779'])">Ref</a></span>). Cholestatic and mixed patterns of injury have been reported. Hepatic effects may occur following severe hypersensitivity reactions (eg, toxic epidermal necrosis, Stevens-Johnson syndrome) and are characterized by immune-mediated symptoms (eg, fever rash, eosinophilia, lymphadenopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8759674','lexi-content-ref-276660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8759674','lexi-content-ref-276660'])">Ref</a></span>). Severe liver injury requiring liver transplantation has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23325533','lexi-content-ref-12358284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23325533','lexi-content-ref-12358284'])">Ref</a></span>). Most cases of liver injury are likely reversible following discontinuation; full recovery may take several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-276660','lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-276660','lexi-content-ref-31984540'])">Ref</a></span>). However, chronic vanishing bile duct syndrome with chronic liver failure has been reported following cholestatic liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8759674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8759674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; dose-related has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794'])">Ref</a></span>). Proposed mechanisms include a toxic metabolite or a hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31984540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset of NSAID-induced hepatotoxicity is generally classified as moderate (30 to 90 days) to long (&gt;90 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chalasani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chalasani.1'])">Ref</a></span>). For ibuprofen, a mean time of 12 days (range: 1 to 42 days) was reported in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31984540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior NSAID-related liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note: </b>Cross-reactivity may occur among propionic acid derivatives (eg, ibuprofen, naproxen, ketoprofen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b> (immediate and delayed) involving the skin (eg, <b>angioedema</b>, <b>urticaria</b>), airways (eg, dyspnea, rhinorrhea), and/or other organs have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Clinical phenotypes of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions include NSAID-exacerbated respiratory disease (NERD), NSAID-induced urticaria/angioedema (NIUA), NSAID-exacerbated cutaneous disease (NECD), and single NSAID-induced urticaria/angioedema or anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26841325','lexi-content-ref-31545385','lexi-content-ref-24117484','lexi-content-ref-30544107','lexi-content-ref-31993263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26841325','lexi-content-ref-31545385','lexi-content-ref-24117484','lexi-content-ref-30544107','lexi-content-ref-31993263'])">Ref</a></span>). Delayed hypersensitivity reactions, including acute generalized exanthematous pustulosis (AGEP), drug rash with eosinophilia and systemic symptoms (DRESS), and <b>Stevens-Johnson syndrome</b> (SJS) have also been associated with ibuprofen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34295789','lexi-content-ref-17982931','lexi-content-ref-25490169','lexi-content-ref-16111447','lexi-content-ref-33528572','lexi-content-ref-15009394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34295789','lexi-content-ref-17982931','lexi-content-ref-25490169','lexi-content-ref-16111447','lexi-content-ref-33528572','lexi-content-ref-15009394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate reactions: Non–dose-related; most reactions (ie, NERD, NECD, NIUA) are non-immunologic related to inhibition of cyclooxygenase-1 (COX-1) with subsequent activation of mast cells and eosinophils causing release of inflammatory mediators including cysteinyl-leukotrienes (cysLTs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Some immediate reactions are IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31496752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31496752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions: Delayed hypersensitivity reactions are T-cell–mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-25749768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate reactions: Rapid; occur within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions (including DRESS, AGEP, and SJS): Varied, generally occurs after 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>), although some patients may develop symptoms within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17982931','lexi-content-ref-25490169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17982931','lexi-content-ref-25490169'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of chronic rhinosinusitis with nasal polyps, family history of NERD, and/or severe asthma may increase the risk of NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>). The prevalence of NERD in adult patients with asthma is ~10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic urticaria increases the risk of NECD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). NSAID-induced reactions are less frequent and less intense when chronic urticaria is in remission or under control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>). Approximately 12% to 30% of patients with chronic idiopathic urticaria develop exacerbations of their disease with use of ibuprofen and other COX-1 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between aspirin and NSAIDs, including ibuprofen (with predominant COX-1 inhibition) have been described in patients with a history of NERD, NECD, and NIUA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Cross-reactivity between aspirin/NSAID and acetaminophen, a weak COX inhibitor, and between aspirin/NSAID and nonselective COX-2 inhibitors (eg, meloxicam, nimesulide) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-17609236','lexi-content-ref-30544107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-17609236','lexi-content-ref-30544107'])">Ref</a></span>). Although selective COX-2 inhibitors (eg, celecoxib, etoricoxib) are generally tolerated in patients with NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21631520','lexi-content-ref-30207919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21631520','lexi-content-ref-30207919'])">Ref</a></span>), cross-reactions may occur, especially in patients with histories of urticaria/angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-24587953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-24587953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity may occur among propionic acid derivatives (eg, ibuprofen, naproxen, ketoprofen) in patients with histories of immediate hypersensitivity reactions to ibuprofen but tolerance to aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26841325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26841325'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, is associated with an increased risk of several kidney-specific effects: <b>Hemodynamically-mediated acute kidney injury</b>, <b>interstitial nephritis</b> (with or without nephrotic syndrome), and <b>renal papillary necrosis</b> in all ages.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodynamically-mediated acute kidney injury (AKI): Hemodynamically-mediated AKI may occur following use of either cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) or nonselective NSAIDs, including ibuprofen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-23360563','lexi-content-ref-25439535','lexi-content-ref-17005625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-23360563','lexi-content-ref-25439535','lexi-content-ref-17005625'])">Ref</a></span>); the risk may be greater with nonselective NSAIDs, especially indomethacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16813969','lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10974130','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16813969','lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10974130','lexi-content-ref-10390124'])">Ref</a></span>). The risk of developing AKI is decreased upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute interstitial nephritis (AIN) with or without nephrotic syndrome: Patients may develop NSAID-associated proteinuria combined with interstitial nephritis and varying degrees of kidney impairment; the “classic triad” of fever, rash, and eosinophilia is less commonly observed in NSAID-associated AIN than with antibiotic-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>). Kidney histology may reveal minimal change glomerulonephritis or membranous nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-31416889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-31416889'])">Ref</a></span>). While use of ibuprofen has been associated with this clinical picture, the risk may be greatest with fenoprofen as compared to other NSAIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>). Proteinuria generally improves within weeks following discontinuation; full recovery may require treatment and take up to a year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Papillary necrosis: Chronic use of NSAIDs, including ibuprofen, has resulted in the development of papillary necrosis, which may occur in conjunction with chronic interstitial nephritis and progressive decline in glomerular filtration rate as a clinical syndrome known as analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12512867','lexi-content-ref-7306246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12512867','lexi-content-ref-7306246'])">Ref</a></span>). However, controversy exists on the degree to which NSAID use increases the risk for chronic kidney disease and analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17410098','lexi-content-ref-32317121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17410098','lexi-content-ref-32317121'])">Ref</a></span>). Acute papillary necrosis may occur following NSAID overdose, especially in a setting of severe dehydration or intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically-mediated AKI: Dose- and time-related; inhibition of cyclooxygenase (COX)-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3045551','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3045551','lexi-content-ref-10390124'])">Ref</a></span>). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Not clearly established. Following inhibition of COX-1 and COX-2 by NSAIDs, arachidonic acid is formed which may be further metabolized to leukotrienes via the lipoxygenase pathway; leukotrienes may increase vascular permeability within glomerular capillaries and peritubular capillaries and increase lymphocyte recruitment and activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Papillary necrosis: Time-related; exact mechanism is not clearly established; may be due to direct toxicity and/or inhibition of prostaglandin-mediated vasodilation resulting in ischemic necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AKI: Rapid; may occur within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Varied; mean time of onset of ~5 months (range: 2 weeks to 18 months) has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:10em;">- Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:12em;">• <b>Note: </b>High cumulative doses (eg, ibuprofen &gt;700 mg/day) may increase the risk for progression of chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17349452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17349452'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- ≥65 years of age (Nash 2019)</p>
<p style="text-indent:-2em;margin-left:12em;">• <b>Note: </b>NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (Brophy 2013, Misurac 2013)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemodynamically-mediated AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting conditions which result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (Baker 2020):</p>
<p style="text-indent:-2em;margin-left:12em;">Volume depletion (eg, due to concomitant diuretic use, nausea, vomiting)</p>
<p style="text-indent:-2em;margin-left:12em;">Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Cirrhosis and ascites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-447795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-447795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:10em;">- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799625','lexi-content-ref-23299844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799625','lexi-content-ref-23299844'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• AIN with or without nephrotic syndrome: Prior history of NSAID-induced nephrotic syndrome; recurrence has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879670'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Papillary necrosis (acute):</p>
<p style="text-indent:-2em;margin-left:8em;">- Massive NSAID ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-25439535'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Papillary necrosis (chronic)/analgesic nephropathy: Chronic concomitant use of other analgesics (eg, aspirin, acetaminophen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension</b> has occurred following early (prophylactic) administration and treatment of patent ductus arteriosus (PDA) in preterm or low birth weight neonates; cases have been reported with both tromethamine ibuprofen (not available in the United States) and L-lysine ibuprofen therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-27692860','lexi-content-ref-30264852','lexi-content-ref-15717178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-27692860','lexi-content-ref-30264852','lexi-content-ref-15717178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; several hypotheses have been proposed. The first relates to timing of treatment in which the administration of drug and PDA closure occurs before the normal decrease in pulmonary vascular resistance has occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458','lexi-content-ref-11988250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458','lexi-content-ref-11988250'])">Ref</a></span>). Another hypothesis involves the effects of the acidic pH of the ibuprofen solution, namely tromethamine buffered solutions, which may lead to precipitation and microembolism of the lung (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-15717178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-15717178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; has occurred within the first hour following the administration of the first or second dose of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458','lexi-content-ref-11988250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458','lexi-content-ref-11988250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Lower gestational age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower birthweight (less than third percentile for age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting pulmonary hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Early administration of treatment (&lt;6 hours postnatal age in premature neonates) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-15717178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785458','lexi-content-ref-11988250','lexi-content-ref-15717178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Maternal hypertension of pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Maternal oligohydramnios (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692860'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F181423"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Hematologic &amp; oncologic: Decreased hemoglobin (17% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Edema (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Maculopapular rash, pruritus (1% to 3%), skin rash (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Fluid retention (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal cramps (1% to 3%), abdominal distress (1% to 3%), abdominal pain (1% to 3%), bloating (1% to 3%), constipation (1% to 3%), decreased appetite (1% to 3%), diarrhea (1% to 3%), dyspepsia (1% to 3%), epigastric pain (3% to 9%), flatulence (1% to 3%), heartburn (3% to 9%), nausea (3% to 9%), nausea and vomiting (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (3% to 9%), headache (1% to 3%), nervousness (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Tinnitus (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Cardiac arrhythmia, increased blood pressure, palpitations, sinus bradycardia, sinus tachycardia</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia, erythema multiforme, skin photosensitivity, urticaria, vesiculobullous dermatitis</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Acidosis, gynecomastia, heavy menstrual bleeding, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Duodenal ulcer, gastric ulcer, gastritis, gingival ulceration, melena, pancreatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Azotemia, cystitis, hematuria</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, decreased hematocrit, eosinophilia, hemolytic anemia, hemorrhage, Henoch-Schonlein purpura, neutropenia, thrombocytopenia, ulcer with hemorrhage</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Abnormal hepatic function tests, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Angioedema, serum sickness</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Abnormal dreams, chills, confusion, depression, drowsiness, emotional lability, hallucination, idiopathic intracranial hypertension, insomnia, paresthesia</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Amblyopia, cataract, conjunctivitis, diplopia, optic neuritis, xerophthalmia</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Decreased creatinine clearance, polyuria, renal papillary necrosis</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Bronchospasm, epistaxis, rhinitis</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection: Ibuprofen (Caldolor):</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypokalemia (4% to 19%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Flatulence (16%), vomiting (22%; children: ≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (4% to 36%; children: ≥2%), eosinophilia (26%), hypoproteinemia (10% to 13%), neutropenia (7% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 1</a>)</span><span class="table-link" style="display:none;">Neutropenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption>
<b>Ibuprofen: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibuprofen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibuprofen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Infection: Bacteremia (13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (12%; children: ≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypertension (≤10%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 2</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, hypotension (7% to 10%), peripheral edema (3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption>
<b>Ibuprofen: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibuprofen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibuprofen)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg every 4 hours for 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypernatremia (7% to 10%), hypoalbuminemia (10%), increased lactate dehydrogenase (7% to 10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distress (≤3%), diarrhea (10%), dyspepsia (1% to 4%), nausea (children: ≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary retention (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Hemorrhage (10%), thrombocythemia (3% to 10%), wound hemorrhage (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Infusion-site pain (children: ≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased blood urea nitrogen (10%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Bacterial pneumonia (3% to 10%), cough (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection: Ibuprofen lysine (NeoProfen)</b> (as reported in premature infants):</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin irritation (≤16%), skin lesion (≤16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypocalcemia (12%), hypoglycemia (12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Enterocolitis (22%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (32%), hemorrhage (32%; primarily intraventricular)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Sepsis (43%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Intraventricular hemorrhage (29%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Apnea (28%), respiratory tract infection (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Edema (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (7%), hypernatremia (7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Decreased urine output (3%), urinary tract infection (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased blood urea nitrogen (7%), increased serum creatinine (3%), renal insufficiency (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Atelectasis (4%), respiratory failure (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined (any formulation):</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hyperglycemia</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distention, cholestasis, gastritis, gastroesophageal reflux disease, intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Neutropenia, prolonged bleeding time</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Reduced intake of food/fluids</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (FDA 2015), cerebrovascular accident (FDA 2015), exacerbation of hypertension (Ruschitzkha 2017), heart failure (FDA 2015), thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, skin rash, Stevens-Johnson syndrome (Sternlieb 1978), toxic epidermal necrolysis (Balint 2014; Barry 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (Yeomans 2018), gastrointestinal inflammation, gastrointestinal perforation (including esophageal perforation, intestinal, stomach) (Yeomans 2018), gastrointestinal ulcer (Yeomans 2018), necrotizing enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Oliguria (Brandstetter 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Jain 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (idiosyncratic) (Chalasani 2021), increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Kay 2013), hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms syndrome (Koca 2016; Roales-Gómez 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Pires 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, scotoma, vision color changes, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Rahman 2014; Misurac 2013), interstitial nephritis (Rahman 2014), renal failure syndrome (Marasco 1987; Poirier 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary hypertension (Bellini 2006; Gournay 2002; Ohlsson 2013)</p></div>
<div class="block coi drugH1Div" id="F181438"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ibuprofen (eg, anaphylactic reactions, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg, bronchial asthma, aspirin intolerance, rhinitis); use in the setting of coronary artery bypass graft (CABG) surgery</p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen lysine (NeoProfen): Proven or suspected infection that is untreated; congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow (eg, pulmonary atresia, severe coarctation of the aorta, severe tetralogy of Fallot); bleeding (especially those with active intracranial hemorrhage or GI bleeding); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis; or significant renal function impairment.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Cerebrovascular bleeding or other bleeding disorders; active gastric/duodenal/peptic ulcer, active GI bleeding; inflammatory bowel disease; uncontrolled heart failure; moderate [IV formulation only] to severe renal impairment (creatinine clearance [CrCl] &lt;30 mL/minute); deteriorating renal disease; moderate [IV formulation only] to severe hepatic impairment; active hepatic disease; hyperkalemia; third trimester of pregnancy; breast-feeding; patients &lt;18 years of age [IV formulation only]; patients &lt;12 years of age [oral formulation only]; systemic lupus erythematosus [oral formulation only].</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">OTC labeling: When used for self-medication, do not use if previous allergic reaction to any other pain reliever/fever reducer; prior to or following cardiac surgery.</p></div>
<div class="block war drugH1Div" id="F181420"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Nonsteroidal anti-inflammatory drug (NSAID) use may increase the risk of hyperkalemia, particularly in patients ≥65 years of age, in patients with diabetes or renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic events: Blurred/diminished vision, scotomata, and changes in color vision have been reported. Discontinue therapy and refer for ophthalmologic evaluation if symptoms occur. Periodically evaluate vision in all patients receiving long-term therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus and mixed connective tissue disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac is recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016b; Horsley 2019; Thorell 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Use of ibuprofen lysine (NeoProfen) is contraindicated in preterm infants with significant renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ibuprofen injection (Caldolor): Must be diluted prior to administration; hemolysis can occur if not diluted.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ibuprofen lysine injection (NeoProfen): May alter signs of infection. May inhibit platelet aggregation; monitor for signs of bleeding. May displace bilirubin; use caution when total bilirubin is elevated. Long-term evaluations of neurodevelopment, growth, or diseases associated with prematurity following treatment have not been conducted. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Prior to self-medication, patients should contact health care provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, or are ≥60 years of age. If patients are using for migraines, they should also contact health care provider if they have not had a migraine diagnosis by health care provider, a headache that is different from usual migraine, worst headache of life, fever and neck stiffness, headache from head injury or coughing, first headache at ≥50 years of age, daily headache, or migraine requiring bed rest. Do not exceed recommended dosages due to an increased risk of GI bleeding. Stop use and consult a health care provider if symptoms do not improve within first 24 hours of use (children) get worse, or newly appear, fever lasts for &gt;3 days or pain lasts &gt;3 days (children) and &gt;10 days (adults). Do not give for &gt;10 days unless instructed by healthcare provider. Consuming ≥3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878493"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Oral liquid products are available in 2 concentrations (concentrated infant drops: 50 mg/1.25 mL [40 mg/mL] and suspension: 100 mg/5 mL [20 mg/mL]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg".</p>
<p style="text-indent:0em;margin-top:2em;">IV ibuprofen is as effective as IV indomethacin for the treatment of patent ductus arteriosus (PDA) in preterm neonates, but is less likely to cause adverse effects on renal function (eg, oliguria, increased serum creatinine) (Aranda 2006; Lago 2002; Ohlsson 2013; Van Overmeire 2000). Ibuprofen (compared to indomethacin) also has been shown to decrease the risk of developing NEC (Ohlsson 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Use with caution in neonates with controlled infection or those at risk for infection; ibuprofen may alter the usual signs of infection. Use with caution in neonates when total bilirubin is elevated; ibuprofen may displace bilirubin from albumin-binding sites.</p>
<p style="text-indent:0em;margin-top:2em;">Avoid extravasation of ibuprofen lysine injection (NeoProfen); IV solution may be irritating to tissues.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F181430"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil: 200 mg [contains coconut oil (copra/cocos nucifera oil)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil Liqui-Gels minis: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil Migraine: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen Minis: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Ibuprofen: 200 mg [gluten free; contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KS Ibuprofen: 200 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin IB: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caldolor: 800 mg/200 mL (200 mL); 800 mg/8 mL (8 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as lysine [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NeoProfen: 10 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL) [fruit flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL) [contains edetate (edta) disodium, fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL [DSC]) [alcohol free; contains fd&amp;c blue #1 (brilliant blue), propylene glycol, sodium benzoate; blue raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (30 mL, 120 mL) [alcohol free, dye free; contains edetate (edta) disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains edetate (edta) disodium, polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Ibuprofen: 100 mg/5 mL (5 mL [DSC]) [contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, quinoline yellow (d&amp;c yellow #10), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Ibuprofen: 100 mg/5 mL (5 mL [DSC]) [alcohol free, dye free; contains corn starch, polysorbate 80, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Motrin: 100 mg/5 mL (30 mL, 120 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, quinoline yellow (d&amp;c yellow #10), sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Motrin: 100 mg/5 mL (120 mL, 240 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen Childrens: 100 mg/5 mL (118 mL) [contains fd&amp;c blue #1 (brilliant blue), polysorbate 80, propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen Childrens: 100 mg/5 mL (118 mL, 237 mL) [contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen Childrens: 100 mg/5 mL (118 mL) [contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, sodium benzoate; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen Childrens: 100 mg/5 mL (118 mL) [dye free; contains polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Ibuprofen Childrens: 100 mg/5 mL (120 mL) [alcohol free, dye free, gluten free; contains polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL, 237 mL) [contains fd&amp;c blue #1 (brilliant blue), polysorbate 80, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL, 237 mL) [contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (5 mL, 10 mL) [alcohol free; contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL [DSC]) [alcohol free; contains corn starch, fd&amp;c red #40 (allura red ac dye), polysorbate 80, quinoline yellow (d&amp;c yellow #10), sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL [DSC]) [alcohol free; contains corn starch, fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL, 120 mL, 237 mL, 240 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (120 mL [DSC], 240 mL [DSC]) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, quinoline yellow (d&amp;c yellow #10), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (120 mL [DSC], 240 mL [DSC]) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, quinoline yellow (d&amp;c yellow #10), sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL [DSC]) [alcohol free, dye free; contains corn starch, polysorbate 80, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (5 mL) [alcohol free, dye free; contains polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (5 mL) [alcohol free, dye free, gluten free; contains fd&amp;c red #40 (allura red ac dye), propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibuprofen Childrens: 100 mg/5 mL (118 mL, 237 mL) [dye free; contains polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants Advil: 50 mg/1.25 mL (30 mL) [alcohol free, dye free; contains edetate (edta) disodium, polysorbate 80, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants Advil: 50 mg/1.25 mL (15 mL) [alcohol free, dye free; contains edetate (edta) disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin Infants Drops: 50 mg/1.25 mL (30 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL, 118 mL, 120 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Addaprin: 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Addaprin: 200 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil: 200 mg [contains methylparaben, propylparaben, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil Junior Strength: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dyspel: 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen: 200 mg [gluten free; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Ibuprofen: 200 mg [gluten free; contains corn starch, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">I-Prin: 200 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IBU: 400 mg, 600 mg, 800 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IBU-200: 200 mg [dye free; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Medi-First Ibuprofen: 200 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin IB: 200 mg [contains corn starch, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provil: 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg, 400 mg, 600 mg, 800 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advil Junior Strength: 100 mg [scored; contains aspartame, fd&amp;c blue #2 (indigo carm) aluminum lake; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Ibuprofen IB Childrens: 100 mg [scored; contains aspartame, fd&amp;c yellow #6(sunset yellow)alumin lake, soybean oil; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin Childrens: 100 mg [contains aspartame, fd&amp;c blue #1 (brill blue) aluminum lake, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Motrin Childrens: 100 mg [dye free; contains aspartame, soybean oil]</p></div>
<div class="block geq drugH1Div" id="F181416"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F181440"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Advil Liqui-Gels minis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Advil Migraine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Advil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ibuprofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.07 - $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Motrin IB Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Advil Junior Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Motrin Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Ibupak Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $1,523.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Caldolor Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg/200 mL (per mL): $0.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg/8 mL (per mL): $3.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ibuprofen Lysine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $206.25 - $273.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NeoProfen Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $646.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Childrens Advil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Childrens Motrin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Ibuprofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.06 - $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Infants Advil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/1.25 mL (per mL): $0.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Motrin Infants Drops Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/1.25 mL (per mL): $0.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Advil Junior Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Advil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (IBU Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ibuprofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.02 - $0.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $0.03 - $0.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $0.05 - $4.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $0.06 - $4.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Medi-First Ibuprofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Motrin IB Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867161"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caldolor: 100 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg</p></div>
<div class="block adm drugH1Div" id="F181435"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or milk.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Caldolor: For IV administration only; infuse over at least 30 minutes (adults).</p></div>
<div class="block admp drugH1Div" id="F52613019"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or milk to decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Shake suspension well before use. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Ibuprofen injection (Caldolor): For IV administration only; infuse over ≥10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Ibuprofen lysine injection (NeoProfen): For IV administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through IV port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed, interrupt TPN for 15 minutes prior to and after ibuprofen administration, keeping line open with dextrose or saline.</p></div>
<div class="block meg drugH1Div" id="F7874617"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg%3D%3D&amp;TOPIC_ID=8547" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F181434"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Management of inflammatory diseases and rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ibuprofen injection (Caldolor):</b> Management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics in adults and pediatric patients ≥3 months of age; reduction of fever in adults and pediatric patients ≥3 months of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ibuprofen lysine injection (NeoProfen):</b> Patent ductus arteriosus: To close a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1,500 g who are no more than 32 weeks of gestational age when usual medical management (eg, diuretics, fluid restriction, respiratory support) is ineffective.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>OTC labeling:</b> Reduction of fever; management of pain due to headache, acute migraine, sore throat, arthritis, or physical or athletic overexertion (eg, sprains/strains), menstrual pain, dental pain, minor muscle/bone/joint pain, backache, and pain due to the common cold and flu.</p></div>
<div class="block off-label drugH1Div" id="F25474800"><span class="drugH1">Use: Off-Label: Adult</span><p>Abnormal uterine bleeding, nonacute; Gout, treatment, acute flares; Pericarditis, acute or recurrent</p></div>
<div class="block mst drugH1Div" id="F181516"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Haltran may be confused with Halfprin</p>
<p style="text-indent:0em;margin-left:2em;">Motrin may be confused with Neurontin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Ibuprofen is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for chronic use in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high-risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Injectable formulations: Both ibuprofen and ibuprofen lysine are available for parenteral use. Ibuprofen lysine is <b>only</b> indicated for closure of a clinically-significant patent ductus arteriosus.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F181500"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> OAT1/3</p></div>
<div class="block dri drugH1Div" id="F181425"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Ibuprofen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Ibuprofen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PEMEtrexed: Ibuprofen may increase the serum concentration of PEMEtrexed.  Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).  Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Ibuprofen may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307763"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F7684272"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage, have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Avoid maternal use of NSAIDs beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours, and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, prescribing information for ibuprofen specifically states to avoid use starting at 30 weeks' gestation.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). The acute treatment of migraine headaches during pregnancy should be initiated with an agent other than an NSAID. If an NSAID is needed as second-line therapy, treatment should be limited to the second trimester and total duration of therapy should be no longer than 48 hours. Ibuprofen may be preferred when an NSAID is needed (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">NSAIDs may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 2019).</p></div>
<div class="block brc drugH1Div" id="F181441"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of ibuprofen in breast milk are available from multiple studies (Rigourd 2014; Townsend 1984; Walter 1997; Weibert 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">• According to the manufacturer, the relative infant dose (RID) of ibuprofen is 0.06% to 0.6% based on the weight-adjusted maternal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Six doses of oral ibuprofen 400 mg were administered to a lactating patient for pain following maxillary surgery (postpartum age not stated). Thirty minutes following administration of the first dose, breast milk concentrations were 13 ng/mL. The highest concentration of ibuprofen in breast milk was 181 ng/mL measured after 20.5 hours. Using the actual weight of the mother and infant, the authors calculated the RID of ibuprofen to be 0.0008% (Walter 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ibuprofen concentrations in breast milk are available from 13 lactating mothers (mean GA at delivery: 36.6 weeks) with a duration of breastfeeding between 12 and 1,270 days. Ibuprofen doses ranged from 400 mg to 1,200 mg/day (mean dose: 1,046 mg/day). The mean concentration of ibuprofen in breast milk was 361.23 mcg/L (range 163.95 to 590.08 mcg/L). Authors of the study calculated the estimated infant dose of ibuprofen via breast milk to be 68 mcg/kg/day (range: 8 to 262 mcg/kg/day) providing a RID &lt;0.38% of the weight-adjusted maternal dose (range 0.04% to 1.53%). Protein content of breast milk decreases over time and ibuprofen is highly protein bound. It was observed in this study that the transfer of ibuprofen into milk decreased with the protein content as well as the duration of lactation. The highest relative infant doses were calculated in premature infants (1.136% and 1.531%) who were both &lt;30 days old during the study (Rigourd 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">A prospective cohort study evaluated the outcomes of breastfed infants whose mothers were taking various medications. Within the study, 21 mother-infant pairs reported ibuprofen exposure (dose, duration, relationship to breastfeeding not provided). There were no cases of diarrhea, drowsiness, or irritability in the breastfed infants (Ito 1993). Based on the available data, adverse events have not been reported in breastfeeding infants and milk production is not affected.</p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002). Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who require pain control peripartum or for surgery outside of the postpartum period (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]). NSAIDs are considered compatible for the treatment of rheumatic and musculoskeletal diseases in lactating patients; ibuprofen is the preferred NSAID (ACR [Sammaritano 2020]). NSAIDs may be used to treat acute migraine in lactating patients (ACOG 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Avoid maternal use of NSAIDs if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013).</p></div>
<div class="block dic drugH1Div" id="F181442"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine and/or potassium.</p></div>
<div class="block mop drugH1Div" id="F181428"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, chemistry profile, occult blood loss and periodic LFTs; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (urine output, serum BUN and creatinine); observe for bleeding, bruising (especially in patients with coagulation disorders or who are receiving anticoagulants); monitor for anemia with long-term therapy; evaluate GI effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation; BP; periodic ophthalmic exams with long-term therapy; signs of infection (ibuprofen lysine); signs of immediate or delayed hypersensitivity reactions.</p></div>
<div class="block rer drugH1Div" id="F181431"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;text-align:justify;display:inline">Plasma concentrations &gt;200 mcg/mL may be associated with severe toxicity</p></div>
<div class="block pha drugH1Div" id="F181419"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>
<p style="text-indent:0em;margin-top:2em;">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>
<div class="block phk drugH1Div" id="F181437"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Analgesic: Within 30 to 60 minutes (Davies 1998; Mehlisch 2013); Antipyretic: Single oral dose 8 mg/kg (Kauffman 1992): Infants ≤1 year: 69 ± 22 minutes; Children ≥6 years: Single oral dose 8 mg/kg (Kauffman 1992): 109 ± 64 minutes; Adults: &lt;1 hour (Sullivan 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum effect: Antipyretic: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: Antipyretic: 6 to 8 hours (Sullivan 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid (85%).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Febrile children &lt;11 years: 0.2 L/kg; Adults: 0.12 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Ibuprofen (Caldolor):</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 6 months to &lt;2 years: 0.31 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 2 to 16 years: 0.23 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Ibuprofen lysine: Premature neonates, GA &lt;32 weeks: Variable results observed: 0.32 L/kg, others have reported: a central compartment V<sub>d</sub> that decreases with increasing PNA and ductal closure (Van Overmeire 2001) and a V<sub>d</sub>, apparent: 0.062 L/kg in 21 premature neonates (GA &lt;32 weeks, PNA: &lt;1 day) (Aranda 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%; Premature infants: ~95% (Aranda 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via oxidation; <b>Note:</b> Ibuprofen is a racemic mixture of R and S isomers; the R isomer (thought to be inactive) is slowly and incompletely (~60%) converted to the S isomer (active) in adults; the amount of conversion in children is not known, but it is thought to be similar to adults; a study in preterm neonates estimated the conversion to be 61% after prophylactic ibuprofen use and 86% after curative treatment (Gregoire 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Ibuprofen (Caldor):</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 3 months to &lt;6 months: 1.3 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months to Children &lt;2 years: 1.8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years to Adolescents ≤16 years: ~1.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 2.22 to 2.44 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Ibuprofen lysine (Neoprofen):</p>
<p style="text-indent:-2em;margin-left:6em;">Premature neonates, GA &lt;32 weeks: Reported data highly variable.</p>
<p style="text-indent:-2em;margin-left:6em;">R-enantiomer: 10 hours; S-enantiomer: 25.5 hours (Gregoire 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">Age-based observations:</p>
<p style="text-indent:-2em;margin-left:10em;">PNA &lt;1 day: 30.5 ± 4.2 hours (Aranda 1997).</p>
<p style="text-indent:-2em;margin-left:10em;">PNA 3 days: 43.1 ± 26.1 hours (Van Overmeire 2001).</p>
<p style="text-indent:-2em;margin-left:10em;">PNA 5 days: 26.8 ± 23.6 hours (Van Overmeire 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 months to 10 years: Oral suspension: 1.6 ± 0.7 hours (Kauffman 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~2 hours; End-stage renal disease: Unchanged (Aronoff 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tablets: 1 to 2 hours; Suspension: 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Children with cystic fibrosis (Scott 1999):</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension (n=22): 0.74 ± 0.43 hours (median: 30 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">Chewable tablet (n=4): 1.5 ± 0.58 hours (median: 1.5 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (n=12): 1.33 ± 0.95 hours (median: 1 hour).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as metabolites (45% to 80%); ~1% as unchanged drug and 14% as conjugated); some feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F181443"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Dolgit | Doloraz | Emifen | Fenbid | I profen | Ibucare | Ibugesic | Ibulgan | Ibusoft | Irfen | Jazofen | Medafen | Monoflam | Neoprofen | Nufen | Prof | Profinal | Sapofen | Spedifen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actron | Actron 600 rapida accion | Actron mujer forte rapida accion | Actron pediatrico | Acuilfem | Acuilfem 15 | Advil | Afebril | Afebril masticable | Algioprofen | Atomo desinflamante ibu | Bistryl | Butidiona | Causalon ibu | Copiron | Dolorsyn termico | Druisel vl | Fabogesic | Fabogesic vl | Fada ibuprofeno | Febratic | Fontol | Ibu apracur | Ibubenitol | Ibucler | Ibudolor | Ibuevanol forte rapida accion | Ibufabra | Ibufec | Ibufix | Ibufull | Ibukasec | Ibulam | Ibulgia | Ibumar | Ibumax | Ibumejoral | Ibumultin | Ibup | Ibupirac | Ibupirac pediatrico | Ibupiretas | Ibuprofenix mujer | Ibuprofeno | Ibuprofeno biocrom | Ibuprofeno bouzen peneco | Ibuprofeno elisium | Ibuprofeno elisium mujer | Ibuprofeno fecofar | Ibuprofeno ilab | Ibuprofeno iraola | Ibuprofeno klonal | Ibuprofeno klonal nf | Ibuprofeno lafedar | Ibuprofeno larjan | Ibuprofeno puntanos | Ibuprofeno purissimus | Ibuprofeno richet | Ibuprofeno richet vl | Ibuprofeno sant gall friburg | Ibuprofeno tauro | Ibuprofeno tauro vl | Ibuprofeno valmax | Ibusi | Ibusol | Ibusol anana | Ibusumal | Ibutafirol | Ibutenk | Ibuxfar | Ibuxim | Ibuzidine | Labsyna | Matrix nucleo disgregable ra | Matrix pediatrico | Motrax | Novogeniol | Novogeniol rapida accion | Pakurat | Ponstin | Ponstinetas | Si end | Sindol | Termokids | Tonal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adolorin ibuforte direkt | Adolorini direkt | Aktren | Kratalgin | Neobrufen rapid | Nureflex | Nurofen | Pedea | Thomaprodol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adiramedica ibuprofen | Advil | Advil 400 double strength | Advil children 2-12 years pain &amp; fever relief | Advil children 2-7 years pain &amp; fever relief | Advil children 7-12 years pain &amp; fever relief | Advil childrens 7-12 years | Advil infant 3 months-2 years pain &amp; fever relief | Advil infants pain &amp; fever relief | Amcal ibuprofen | Apohealth children's ibuprofen | Apohealth children's ibuprofen infant | Apohealth childrens ibuprofen | Apohealth ibuprofen | Blooms the chemist ibuprofen | Brufen | Bugesic | Chemists own ibuprofen | Chemists' own children's ibuprofen infant | Chemists' own children's ibuprofen pain &amp; fever 6 months - 12 years | Chemists' own children's ibuprofen pain &amp; fever suspension 6 months - 12 years | Chemists' own ibuprofen | Chemists' own ibuprofen double strength | Chemists' own ibuprofen long lasting | Chemists' own ibuvance | Chemmart pharmacy ibuprofen | Children's ibuprofen | Cipla pain relief for little kids ibuprofen | Coles ibuprofen | Discount drug stores ibuprofen | Ethics ibuprofen | Fenpaed | Fenpaed double strength | Gofex | Hedafen ibuprofen | Help@hand for pain &amp; inflammation ibuprofen | Herron blue | Herron blue kids 7+ | Herron ibuprofen blue | I ibuprofen | Ibusoft | IbuVance | Medichoice ibuprofen | Medichoice ibuprofen for kids | Medichoice ibuprofen minicaps pain and inflammation | Medihealth ibuprofen | Medix ibuprofen | Medix ibuprofen double strength | Medix ibuprofen mini caps pain &amp; inflammation | Mendeleev children's ibuprofen | Neo health ibuprofen | Neofen red | Neohealth ibuprofen | Noumed ibuprofen suspension for children 3 months to 5 years | Noumed ibuprofen suspension for children 5 to 12 years | Nurofen for children | Nurofen for children 3 months - 5 years | Nurofen for children 5-12 years | Nurofen for children 7+ years | Nurofen for children baby 3+ months | Nurofen junior | Nurofen zavance | Nyal ibuprofen | Panafen ib | Pharmacy care ibuprofen | Pharmacy choice ibuprofen | Pharmacy choice ibuprofen children's | Pharmacy health ibuprofen | Pharmacy health ibuprofen suspension for baby 3 months+ | Pharmacy health ibuprofen suspension for children 3 months to 5 years | Pharmacy health ibuprofen suspension for children 5 to 12 years | Pharmacy own ibuprofen | Priceline ibuprofen | Priceline pharmacy ibuprofen | Priceline pharmacy ibuprofen suspension for children 3 months to 5 years | Priceline pharmacy ibuprofen suspension for children 5 to 12 years | Proven | Rafen | Soul pattinson ibuprofen | Spiro lifecare ibuprofen | Terry white chemists ibuprofen | Terry white chemmart ibuprofen | Terrywhite chemmart ibuprofen | Terrywhite chemmart ibuprofen suspension for children 3 months to 5 years | Terrywhite chemmart ibuprofen suspension for children 5 to 12 years | Trust for kids ibuprofen infant drops | Trust ibufen | Trust ibuprofen | Wagner health children's ibuprofen | Wagner Health Childrens Ibuprofen | Wagner Health Ibuprofen</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Advel | Antiflam | Arafa | Bufen | Chemofen | Deprofen | Diprofen | Erofen | Esrufen | Flam | Flamex | Flamic | Ibufen | Ibuflam | Iburex | Ibutab | Inflam | Neoflam | Noflam | Norfen | Profen | Rapofen | Rebufen | Reufen | Reumafen | Serviprofen | Tyflam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Algidrin Pediatrico | Brufen | Bufedon | Ibu slow | Ibucaps | Ibuprofen eg | Ibuprofen ratiopharm | Ibuprofen sandoz | Ibuprofen teva | Ibuprofene eg | Junifen | Malafene | Motrin | Nurofen | Perdotensio</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Bufalgan | Ibufen | Ibufil | Ibuprofene | Ibuprofene tm | Ibuprofene ubigen | Iprofene | Lexofen | Paidofebril | Trifene</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Blokmax for kids | Brufen | Flexistad junior | Ibudolor | Ibufen | Ibuprom | Ibuprom optima | Ibuprom sprint | Ibuprom sprint max | Iburapid kids | Mig | Mig junior | Milofen kids | Nurofen | Nurofen express | Panactiv | Panactiv forte | Pedea | Syafen | Upfen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Advil | Algi reumatril | Algy-flanderil | Alivium | Aludor | Artril | Atrofem | Buprovil | Buscofem | Capsfen | Dalsy | Doraliv | Febsen | Ibucaps | Ibuflex | Ibufran | Ibuliv | Ibupril | Ibuprofeno | Ibupromed | Ibuprotrat | Ibuvix | Lombalgina | Medmulher | Motrin | Novalfem | Otiun | Pralivio | Sanafen | Spidufen | Termomed ibup | Vantil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Algifor | Algifor dolo forte | Algifor Dolo Junior | Brufen | Iproben | Irfen | Optifen Junior | Spedifen</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Advil | Algofene | Bufalgan | Bufenol | Dolven | Ibu care | Ibuprofene | Ibusoft | Iprofene | Paidofebril | Pedifen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actron | Actron pediatrico | Adfen | Bediatil | Bladex | Deucodol | Dolgex | Esanterm | Ibu | Ibu 2 | Ibucalm | Ibufas | Ibufren | Ibukids forte | Ibupirac | Ibuprofeno | Ipson | Niofen | Niofen forte | Painpac | Pediaprofen | Pironal | Pyriped | Yetro</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Abrofen | An rui ke | BANG QI | Bo fei te | Di er luo | Fen ke | Fen ni kang | Fenbid | Ji hao | Jian de lin | Jin lai fen bu de | Motrin | Si bai de | Spedifen | Tai bao | Tuo en | Ya wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Actron | Actron max | Advil | Advil children | Advil fastgel | Advil max | Alcadol | Alkadol | Asulpin | Biopen | Biprofen | Bufedol | Buprofen | Buril | Dafenal | Diantal | Diantal pediatrico | Dol | Dolgud | Doliflam | Dolinstant | Dolivium | Dolmaral | Dolonet | Dolorsin | Dolotrin children | Doraliv | Dristancito nf ninos | Espidifen | Fai dol | Febrifen | Femen | Fenpic | Freedol | Frenidol | Gelpiron | Gofen forte | H-loniten | Ibudol | Ibudol soft | Ibuflash | Ibuflash forte | Ibumer | Ibupiretas | Ibupirino | Ibuprofar | Ibuprofeno | Ibuprofeno bcn | Ibuprofeno mk | Infibu | Infredos | Kalmadol children | Kalmadol elc | Kapredol | Ketonoz | Lutifen | Mejoral ultra | Mejoralito | Mejorflex | Motrin | Multidol | Multidol express | Niofen | Notts doraliv ninos | Oren | Painless dolor | Pedea | Pedialab fever fast | Periofem | Pire fen | Pirefen | Profex | Promofen | Qbedol | Rodalgin | Smadol | Suprifeno | Trosifen | Vencedol | Vonprofen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Advil | Apo ibuprofen | Brufen | Ibalgin | Ibuberl | Ibudolor | Ibuprofen apotex | Ibuprofen dh | Ibuprofen dr.max | Ibuprofen farmalider | Iprofenex | Nurofen | Nurofen pro deti | Nurofen pro deti jahoda | Pedea | Solpaflex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aktren | Aktren spezial | Anco | Contraneural | Dignoflex | Dolgit | Dolo puren | Dolormin | Dolormin instant | Dysdolen | Esprenit | Exneural | Ibu | Ibu 1a pharm | Ibu benuron | Ibu kd | Ibubeta | Ibuflam | Ibufug | Ibuhexal | Ibuphlogont | Ibuprofen berco | Ibuprofen ct | Ibuprofen milinda | Ibuprofen sandoz | Ibuprofen stada | Ibuprofen temmler | Ibutad | Ibutad akut | Ilvico grippal | Imbun | Jenaprofen | Lesss | Medokal | Nurofen | Optalidon ibu | Parsal | Pedea | Proff schmerzkapseln | Pyracophen | Schmerz dolgit | Seclodin | Spalt liqua | Spalt mobil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Advil max | Artran | Colbufen | Espidifen | Femmex plus | Frevac | Iberofeno | Ibucedin | Ibufar | Ibufen | Ibukid | Ibumen | Ibuprofen feltrex | Ibuprofen Inmenol | Ibuprofeno | Ibuprofeno exels | Ibuprofeno mk | Ibuwin | Ibuwin forte | Iferin | Inafeb | Suprofen teen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Afebril | Analgion | Analgion forte | Analgion infantil | Bediatil | Buprex | Disfebral | Disfebral fast | Dolfemin | Dolonet forte | Dolorgesic | Dolorgesic forte | Efficol forte | Fabogesic | Febroxial | Femen | Femen forte | Hg iprofen | Ibufen | Ibuflash | Ibuprofeno | Ibuprofeno genfar | Ibuprofeno mk | Ibuprofeno nifa | Ibupront | Ibuprotofis | Ibupstar | Ibusol | Ibutron flash | Ibuwin | Ibuwin forte | Ibuwin plus | Iprofen | Ipson | Kroxifeno | Marbux | Motrin | Multidol | Nefor | Probinex | Profem | Profinal | Rafican | Sindlor | Sinfebril | Tasifen | Tenvalin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Advil | Brufen | Brumare | Forsium | Ibufen | Ibuhexal | Ibumax | Ibumetin | Ibusan | Ibustar | Ipren | Larofen lastele | Motrin | Neoprofen | Noritis | Nurofen | Nurofen strawberry | Nypren | Solpaflex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alphafen | Anabruf | Brufen | Flabu | Flamotal | Ibucalmin | Ibufen | Ibuhexal | Mafo | Marcofen | Maxiprofen | Megafen n | Peopobruf | Pradol | Profinal | Profusol | Rapifen | Ultrafen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Algiasdin | Algidrin infantil | Algidrin Pediatrico | Apirofeno | Asmara | Babypiril | Dalsy | Dolorac pediatrico | Doltra | Escarmine | Espididol | Fiedosin | Gelofeno | Geloprofen | Ibubex | Ibudol | Ibufarmalid | Ibukern | Ibumac | Ibuprofeno aldo union | Ibuprofeno apotex | Ibuprofeno benel | Ibuprofeno cinfa | Ibuprofeno davur | Ibuprofeno durban | Ibuprofeno farmasierra | Ibuprofeno kern | Ibuprofeno Normon | Ibuprofeno ratiopharm | Ibuprofeno sandoz | Ibuprofeno stadapharm | Ibuprofeno teva | Ibuprofeno winadol | Junifen | Neobrufen | Neobrufen retard | Nodolfen | Nurofen | Paidofebril | Pedea | Ratiodol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Betafen | Gofen | Profen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Burana | Femapirin | Ibuxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Advilcaps | Advilmed | Antarene | Gelufene | Ibupradoll | Ibuprofene biogaran | Ibuprofene mylan | Ibuprofene mylan conseil | Ibuprofene RPG | Nureflex | Nurofen | Nurofencaps | Nurofenpro | Spifen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Advil liqui gels | Anadin ibuprofen | Anadin Joint Pain | Anadin liquifast | Anadin ultra | Boots ibuprofen 3 months plus | Brufen | Calprofen | Cuprofen | Dexcel Ibuprofen | Femafen | Feminax Express | Fenbid | Fenpaed | Feverfen | Flarin | Flarin Joint &amp; Muscular Pain Relief | Fleximex | Galpharm ibuprofen | Galpharm migraine relief | Galprofen | Ibrufhalal | Ibu slo | Ibucalm | Ibular | Ibuprofen kent | Ibuprofen sandoz | Inabrin | Mandafen | Maxagesic | Novaprin | Novaprin nova hc | Nurofen | Nurofen (GSL) | Nurofen (P) | Nurofen back pain | Nurofen express | Nurofen for children strawberry | Nurofen for Children Strawberry Singles | Nurofen joint &amp; back pain relief | Nurofen Maximum Strength Migraine Pain | Nurofen migraine | Nurofenpro | Orbifen | Proflex | Radian b | Seclodin | Suspren | T&amp;r ibuprofen | Teva migraine relief</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Anfen | ENAFEN | Letafen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Algofren | Buscofem | Nurofen for children</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Advil | Bifen | Brufen | Dae hwa ibuprofen | Febryn | Ibrufen | Ibufac | Infacalm | Jecefarma ibuprofen | Korus ibuprofen | Neutropain | Nurofen | P fen | Parkins | Perofen | Potofen | Profen | Schufen | Slow ibuprofen | Tai guk ibuprofen | Trifene | Uni ibuprofen | Vicbrofen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Brufen Effect | Dalsy | Dalsy forte | Fidiprofen | Ibuprofen alkaloid | Ibuprofen belupo | Ibuprofen farmal | Ibuprofen Pliva Forte | Ibustar | Neofen | Nurofen | Nurofen forte | Nurofen rapid forte | Nurofen za djecu | Pedea | Rapidol | Rapidol S | Spidifen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Advil ultra | Algoflex | Algoflex rapid | Brufen | Dolgit | Dolgit akut | Dolowill baby | Ibuhexal | Ibulos | Ibustar | Nurofen | Pedea | Rapidophen | Solpaflex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anafen | Arthrifen | Axofen | Brufen | Bufect | Bunofa | Dofen | Dolofen-f | Ethifen | Farsifen | Febryn | Fenatic | Fenbid | Fenris | Hufagripp tmp | Ibufen | Ifen | Iprox | Lexaprofen | Mofen | Moris | Motrin | Nofena | Novaxifen | Ostarin | Prifen | Profen | Proris | Prosic | Prosinal | Rhelafen | Ribunal | Shelrofen | Stelar | Xepafen forte | Yariven | Zentarin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Brufen paediatric | Brupro | Bufigen | Buplex junior | Easofen for children strawberry | Fenopine | Nurofen for children cold &amp; flu &amp; pain orange | Nurofen for children cold &amp; flu &amp; pain strawberry | Nurofen rapid relief | Provin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Adex | Ibufen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfam | Arfen | Bren | Brufen | Brunes | Cipgesic | Fenlong | Ibubid | Ibucon | Ibuflamar | Ibugesic | Ibular | Ibuspan | Ibusynth | Ibutas | Myofen | Neurophen | Reducin | Tricoff | Tudofen</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Brufemel | Ibuprofen awa | Kinprofen | Profedain | Profedin | Profen | Rexofin</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Alvofen express | Ibufen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Algidrin | Algopirina febbre e dolore | Antalfort | Arfen | Arfen pronto | BENATIA Bambini | Brufen | Brufenlik | Buscofen | BuscofenAct | Calmine | Dolibloc | Doliprokid | Edenil | Fenkid | Fevralt | Fluibron febbre e dolore | Ganaprofene | Gineflor | Ginenorm | Ibubaby | Ibuprofene doc generici | Ibuprofene dr. max | Ibuprofene eg | Ibuprofene sandoz | Ibuprofene zentiva | Kendo | Levifen | Moment | Momentact | Momentact analgesico | Momentkid | Nurofast | Nurofen febbre e dolore | Nurofen febre e dolore | Nurofencaps | Pavik | Pedea | Rofixdol febbre e dolore | Sinifev | Spididol Analgesic | Vicks febbre e dolore</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Balkaprofen | Brufen | Doloraz | Fenbid | Fleximex | Ibugesic | Ibuphil | Iburam | Isofen | Jofen | Midofen | Nashat | Profast | Profast forte | Rupan | Sapofen | Taskine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anflagen | Bluton | Bruf | Brufen | Buburone | Butylenin | Chilka chugai | Feria | Fescholin | I.b. | Iborufen | Ibuframen | Ibulief | Ibuprocin | Ibuprofen amel | Ibuprofen mita | Ibuprofen ohara | Ibuprofen sawai | Ibuprofen tatumi | Ibuprofen tsuruhara | Iputes | Lamidon kowa | Landelun | Landelun tsuruhara | Liptan merck hoei | Liptan taiyo | Meridon ib | Mynosedin | Nagifen isei | Nagifen s.s. seiyaku | Napacetin | New kerorin e | Nobfen | Nobgen | Nobgen ace | Ringl ib | Sednafen taisho | Unipron</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asfen fc | Betafen | Bren | Brufen | Brufen paediatric | Brufen retard | Brufol | Brumed | Brunes | Calfen | Daprofen | Fenpro | Gofen | Ibu | Ibucos | Ibufast | Ibufen | Ibufil | Ibuflam | Ibulite | Ibumex | Ibun | Iburin | Ibut | Ifen | Markvil | Medifen | Ml ibuprofen | Neoprofane | Nurofen | Nurofen migraine | Okagesic | Orbifen for children | Ossfen | Pedifen | Ponafen | Profen | Triofen | Ubimol | Zorafen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Advil | Albofen bill | Allopan | Allyfen | Alopan | Alupen | Arfen | Bebyzal | BR Ibufen | Brepin s | Brongfen | Brufen | Budipan | Burofon | Carol | Champ ibufen | Cleanfen | Cobo | Coldaewon kids ibufen | Coldaewon zero ibufen | Comet | Coritussal f | Dafen | Dafen q | Dexfen | Diapen | Dongkoo ibuprofen | Dosifen | Encafen | Encapen | Eve one q | Exipren | Ezn 6 any | Fullopain | Greenfen | Haispen | Hanopen | I profen f | Ibu | Ibu x | Ibuduo | Ibufen | Ibufenon | Ibunal | Ibunewfen | Ibuone qs | Ibuprofen cho a | Ibuprofen dongindang | Ibuprofen dongyang | Ibuprofen hana | Ibuprofen hangook | Ibuprofen samsung | Ibuprofen samwoo | Iburoen | Iburofen | Iburon | Iburus | Ibususpen | Ifenosin | Inberol | Inbromin | Ipren | Irofein | Irofen | Ivupan | Keypain | Kids&amp;fen | Kikilofen | Lamidon | Lapin kids | Lc phen | Lidopain | Logphen | Lupien | Mcfen | Medicofen | Mediphen | Medrapen | Migfen | Monitin | New ibufen | Onopain | Pain angel ibu | Panaphen | Paren | Penbon | Penzal w ibuprofen | Picopen | Pofen | Polyene | Prufen | Q sen | Rheumedon | Rheutis | Rifen | Riorupen | Rofen | Rupien | Rurupino | S vil ibu | Scopen | Speedic | Speedpain nano | Speedpen nano | Taksen 400 ibuprofen | Tatanal | Trisfen | Ttotto | Upotan | Wannabe olive | Yuhan ibuprofen | Zeropain | Zorfen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Advil | Balkaprofen | Brufen | Fenbid | Fleximex | I profen | Ibucare | Ibugesic | Irfen | Jazofen | Kendo | Omafen | Prof | Profinal | Sapofen | Saridon N</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo ibuprofen | Brufen | Captain | Dimidon | Doloraz | Febridex | Fleximex | Ibugesic | Pediafen | Pedifen | Perofen | Profinal | Sapofen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brumare | Ibufanti | Ibufen | Ibufug | Ibugard | Ibumetin | Ibuprom | Ibuprom express | Ibusan | Motrin | Nurofen | Nurofen forte | Nypren</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Ibu | Ibuhexal | Ibuprofen ct | Ibuprofen eg | Ibuprofen sandoz | Imbun | Malafene | Nurofen | Optalidon | Schmerz dolgit | Solufen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo ibuprofen | Brufen | Brumare | Burana | Dolormin migraene | Forsium | Ibufen | Ibugard | Ibugesic | Ibumax | Ibuprof | Ibusan | Ibustar kids | Irfen | Motrin | Neoprofen | Nurofen | Nurofen berniem | Nypren</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Agifene | Algantil | Algofene | Brufen | Dolifen | Ibumac | Intralgis | No dol fen | Nurodol | Prodol | Trifene</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Actron | Adopren | Advil | Advil 12 horas | Advil infantil | Advil max | Afleno | Aflusil | Ainex | Aldofen | Algidol | Arbufentab | Bestafen | Brixsons | Butacortelone | Cadoil | Carone | Citalgan | Days | Defixod | Dipofen | Diprodol | Dolprin | Dolprofen | Dolver | Dulfan | Eufenil | Eufenil forte | Febratic | Fidoin q | Gelidol | Gelubrin | Gobrosan | Ibuflam | Ibuflex | Ibuprofeno | Ifentil | Infantil motrin | Inpained | Jarisoft | Medifen | Mejorultra | Motrin | Nafendol | Neo melufen | Neobrufen | Nuropren | Piradol | Pro xb | Probuxil | Quadrax | Realdrax | Sindolen | Tabalon | Tempra fen | Viczen | Zoafalet h</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel ibuprofen | Brufen | Brusic | Cp pharma ibuprofen | Evofen | Ibufac | Ibufen | Inflafen | Nurofen express | Profinal | Prufen | Winofen | Zorafen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Alapharm ibuprofen | Alben ibuprofen | Astropen | Avrofen ibuprofen | Babuflam | Benprofen | Bio profen | Bioraj ibuprofen | Bkb vibumol | Bond ibuprofen | Brufen | Brustan n | Bucaldol | Bulprofen | Chemofen | Children's ibuprofen | Dana lam | Danbufen | Darprofen | Drugzone ibuprofen | Elbufen | Eminent drugs ibuprofen | Emprofen | Epl ibuprofen | Esefen | Espen | Eurofen | Fatibufen | Friendship ibuprofen | Galen's ibuprofen | Garyfen | Gauze ibuprofen | Genafen | Gilgal ibuprofen | Glopafen | Graprofen | Ibuage | Ibuflam | Ibumed | Ibupain | Ibupkris | Ibuprocel | Ibuprofen bp | Ibusar | Ibuten | Ibuvil | Jesifen | Jopan profen | Jsp ibuprofen | Kayhelt ibuprofen | Leyfen | M &amp; b ibuprofen | Makupar | Multifen | Nalfen forte | Napfen | New divine vibumol | Norprofen | Nosak ibuprofen | Nurofen advance | Nurofen express | Obnoprofen | Ocprofen | Pal ibuprofen | Peace ibuprofen | Piccan | Shreefen | Softhealth ibuprofen | Stevufen | Sunymet ibuprofen | Tabalon | Tabufen | Talibex ibuprofen | Taskine | Tramibu | Ultfen | Vemfen | Vpl ibuprofen | Westmed ibuprofen | Zedfen kid | Zestefen | Zonason ibuprofen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Advil reliva | Antiruggine | Brufen | Ibosure | Ibuprofen actavis | Ibuprofen apotex | Ibuprofen htp | Ibuprofen sandoz | Ibuprofen teva | Leidapharm ibuprofen | Nurofen | Nurofen fastine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Ibugard | Ibumetin | Ibuprox | Ibux | Neoprofen | Nurofen | Nurofen forte | Nurofen junior | Nurofenpro | Pedea</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Advil | Brufen | Ethics ibuprofen | Fenapaed | Ibuprof | Ibuprofen apotex | Nurofen | Nurofen for children | Nurofen for children 5-12 years | Nurofen zavance | Pharmacy health ibuprofen | Your pharmacy ibuprofen</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omafen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Afebril | Alfadol | Alivium | Anafidol | Anaflex mujer NF | Apo ibuprofen | Banes | Banes forte | Biodol | Bren | Doladol | Dolfarb | Dolin forte | Dolobay kids | Dolocheck plus | Dolodif kids | Doloflam extraforte | Dolokid s | Dolomax | Dolomil | Dolonet | Doloral | Doloral forte | Dorelin | Ebufac | Febryn | Flamadol | Flamalgesico | Gesic | Gofen | Ibufas | Ibufenol | Ibumejoral | Ibupirac | Ibupirol | Ibuprofeno | Ibusol | Lefebron | Macrogesic | Mediflam | Mediflam ninos | Metradol | Midol rapid action | Molargesico | Motrin | Multigesico | Natudol | Nonpiron | Pironal | Pirovan | Plidocheck plus | Profen kids | Profinal | Provon | Saldeva | Terbofen</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Advil | Anvil | Brufen | Bufen | Dolafen | Dolan fp | Fasgesic | FeverFree | Fevral | Ibuped | Idyl | Medbufen | Medicol i | Morexen | Mutrim | Myvil | Nurofen | Profen | Rheuxan | Saphfen | Skelan | Sqfen | Ynex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aksofen | Algofen | Ambrofen | Amofen | Anglofen | Azofin | B fen DS | Baprofen | Baxfen | Befen | Bellfen | Bludol | Bludol ds | Blufen | Boschofen | Bril | Bril ds | Brofanic | Brofanic ds | Brucam | Brufedin | Brufen | Bruflet | Brugesic | Brunac | Brusan | Bruwell | Budex ds | Deltafen | Dolofen | Dorafen | Eprofen | Evagesic | Fenbro | Fufen | Glare ds | Glitfen | Hugon | Ibtol | Ibu profen ds | Ibu slow | Ibucil | Ibufen | Ibufin | Ibugesic | Ibulis | Ibumid | Ibumor | Ibuperk | Ibuquik | Iburin | Ibuser | Ibusim ds | Ifen | Inflam | Inzel | Iodofen | Jaefen | Jazofen | Karbufen | Kata ds | Legesic | Mayfanax | Meblot | Meblot sr | Medfen | Mefen | Megafen | Mufen | Mybrofen | Newibu | Newibu ds | Novofen | Nuprin | Nuprofen | Nurofen ds | Ocefen | Ofen | Ottofen | Pabrofen | Pango | Pedifen | Pharfen | Profen | Promin | Prufie | Pyrofen | Radifen | Ramafen | Rapifen | Rebugen | Regofen | Resfen | Rhunor | Ribunal | Rofen | Ruberin | Rumafen | Rumin | Selprofen | Semorfen | Skifen | Synofen | Tabrofen | Tagafin | Torfen | True-fen | Werridal | Wilfen | Winkidofen ds | Xaleve | Xiben | Zayfen | Zefen | Zofen | Zufen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Axoprofen | Babyfen | Bolinet | Brufen | Bufenik | Ibalgin | Ibufen | Ibufen d | Ibum | Ibum comfort | Ibum express | Ibum femina | Ibum forte | Ibum forte minicaps | Ibum Supermax | Ibuprofen Dr. Max | Ibuprofen hasco | Ibuprom dla dzieci | Ibuprom max sprint | Ibutact | Ibuteva max | Ibuxal | Ifenin dla dzieci | Kidofen | Kidofen max | Metafen ibuprofen | Mig | Milifen | Nurofen | Nurofen dla dzieci Forte | Nurofen express femina | Nurofen express forte | Nurofen menstrual | Pediprofen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Advil | Children's ibuprofen | Infants Ibuprofen | Menadol | Motrin | Motrin childs | Motrin ib | Motrin infants</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Arfen | Brufen | Brufen liq | Danofen | Dimidon | Dolocyl | Ib u ron | Ibudol | Ibuprofeno | Ibuprofeno algik | Ibuprofeno Farmoz | Ibuprofeno Pharmakern | Imofen | Inabrin | Moment | Motrin | Nurofen xpress | Nurofen zavance | Pedea | Solufen | Trifene | Zip a dol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actron | Actron pediatrico | Afebril | Afebril forte | Algidol kids | Antidol pediatrico | Banes | Buenox | Calmadol | Carbofeno | Cariodent | Cenflam | Dolgex | Dolgex forte | Dutrifen | Etidol | Fabogesic | Fabogesic ninos | Febratic | Finidol | Finidol forte | Finidol plus | Ibu algyn | Ibu algyn forte | Ibu clerinax | Ibu contradol | Ibu denene | Ibu evanol | Ibu evanol forte | Ibu kids | Ibu metaljina | Ibu temprilan | Ibucler | Ibudolanet | Ibufil | Ibuflam | Ibuflam pediatrico | Ibugesic | Ibulib | Ibumetaljina | Ibunest | Ibupan | Ibupirac | Ibupirac a.p. | Ibuprofeno caplin point | Ibuprofeno catedral | Ibuprofeno cellofarm | Ibuprofeno eximfarma | Ibuprofeno genfar | Ibuprofeno medinac | Ibuprofeno millet | Ibuprofeno p.a.n | Ibuprofeno vivele | Ibusol | Ibusol forte | Ibusol pediatrico | Ibuterm | Ipson | Ipson forte | Kevadon ibuprofeno | Kitadol pediatrico | Kitadol rapid | Movidol ibu | Niofen | Niofen forte | Niofen lc | Pediaprofen | Pediaprofen forte | Profenol | Sindol | Somadol | Vantril | Vantril retard</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Advil | Advil Liqui-Gels | Apo-Ibuprofen | Brufen | Brufen Retard | Children's Advil | Dolgit | Doloraz | Dolormin Extra | Emifen | I-Profen | Ibu | Ibugesic | Medafen | Nurofen Children | Omafen | Panafen | Perofen | Prof | Profinal | Profinal Paediatric | Remofen | Sapofen | Sapofen Junior</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abfen | Adagin | Advil ultra forte | Algin baby | Biofen | Biofen forte | Brufen | Brufen retard | Ibalgin baby | Ibalgin express | Ibalgin junior | Ibuprofen arena | Ibuprofen dr.max | Ibuprom | Ibuvalen | Inflanor | Inflanor forte | Marcofen | Nurofen immedia ultra | Nurofen junior | Paduden | Panafen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Advil | Advil for children | Advil maximum | Apo ibuprofen | Bolinet | Brufen | Bumidol | Ibufen | Ibuprofen hemofarm | Ibuprom sprint | Maxicold for child | Mig for babies | Mig for children | Nebolin | Next uno express | Novigan | Nurofactor | Nurofen | Nurofen express | Nurofen express forte | Nurofen for children | Nurofen ultracap | Nurofen ultracap forte | Pedea | Sedalgin sprint</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Children's advil | Emifen | Fenbid | Ibugesic | Jazofen | Junifen | Medafen | Nufen | Nurofen | Prof | Profinal | Sapofen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Burana | Ibumetin | Ibuprofen abece | Ibuprofen apofri | Ipren | Iprensa | Nurofen | Nurofen jordgubb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bifen | Brufen | Ibuloid | Nurofen | Nurofen express | Sugafen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Brufen | Ibubel | Ibuprofen inn farm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Advil | Apo ibuprofen | Brufen | Dolgit | Ibalgin | Ibalgin rapidcaps | Ibuprofen dr.max | Ibuprofen farmalider | Ibuprofen rapid apotex | Ibuprofen stada | Nurofen | Nurofen pre deti | Panactiv | Pedea | Solpaflex | Tempasa</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Actiflam | Ibuprofene</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Ibufeno</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Acprofen | Ambufen | Anbifen | Aprofen | Babefen | Bethofen | Borafen | Borakid | Brofen | Brufen | Brugin | Brumed | Bruprin | Brusil | Brusoft | Buflex | Bumed | Bunofen | Buprofen | Burafen | Busofen | Cefen | Coprofen paediatric | Deflem | Duran | Fafen | Fob fen | Forbufen | G-fen | Greatofen | Heidi | I Fen | I profen | Ibo | Ibrofen | Ibru | Ibucin | Ibucin R | Ibufac | Ibufex Paediatric | Ibugesic | Ibukids | Ibulan | Ibuman | Iburen | Junimol | Kidifen | Mano Bruzone | Nurofen zavance | Omnifen | Ostofen | Penofen | Pharmafen | Pippen | Prefen | Profen | Profena | Profeno | Profensic | Rufan | Ruprofen | Schufen | Suphen | Tofen | Tonifen | Trofen | Umafen | Venofen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adofen | Balkaprofen | Balkaprofene | Brufen | Buprofen | Cycloff | Dolven | Gelufene | Ibuphil | Moment | Novafen | Pedea</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apireks | Brufen | Bruprex | Brus | Ibu | Ibu-fort | Ibufen | Ibutrit | Pedifen | Profen | Profen fort | Repozal | Rofen | Siyafen | Ultrafen | Upren</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anflagen | Arfen | Artofen | Brofen | Buburone | Bufen | Buprofen | Easifon | Guasheaton | Ibu | Ibufen | Ibulin | Idofen | Illume | Iproefen | Iprofen | Iputon | Kortufen | Librofem | Mobufen | Neoprofen | Nobafon | Nobgen | Profen | Profenil | Sconin | Scoton | Serviprofen | Shouenlin | Suyoubao ib | Tarein | Tolax | Yonfupharm ibuprofen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Affida express | Affida max express | Blokmax for kids | Bofen | Bolinet | Brufen | Brufen rapid | Burana | Darfen express | Darfen kids | Darfen kids forte | Eurofast | Eurofast express | Gofen | Ibufen | Ibufen d | Ibufen for children | Ibufen forte | Ibufen junior | Ibunorm | Ibunorm baby | Ibuprofen baby | Ibuprofen darnitsa | Ibuprom extra | Ibuprom sprint | Ibuprom sprint max | Ibupron | Ibutard | Imet | Imet 2 | Imet 4 | Novigan | Novo profen | Nurofen | Nurofen express | Nurofen express forte | Nurofen for children | Nurofen for children forte | Nurofen kids forte | Orafen | Solpaflex | Termidol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agofen | Asfen fc | Axcel ibuprofen | Betafen | Brumed | Fenpaed | Gofen | Ibucach | Ibumex | K fen | Medifen | Nurofen | Nurofen express | Nurofen for children | Simfen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Actron | Actron pediatrico | Argifen | Bioprofen | Fabogesic | Fabogesic ninos | Febratic | Fluxus | Ibubenitol | Ibuevanol rapida accion | Ibumultin | Ibupirac | Ibupirac fast | Ibupirac pediatrico | Ibupiretas | Ibuprofeno | Ibusol | Ibutenk | Perifar | Ponstinetas | Prontopiren | Zolpirol NF</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anapir | Bioprofen | Brane | Brugesic | Buprodol | Dologesic | Dologesic fem | Femicaps | Femmexplus | Ibucaps | Ibufen | Ibumax | Ibun | Ibuprin | Ibuprofeno | Ibuprofeno-gc | Ibuprofeno-penta | Ibuvin | Ibuwin forte | Iporet | Iprofene | Lumbax | Maydol | Mestral | Motrin | Nanprofen | Pedibu</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">A.t ibuprofen | Sosfever fort</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-Ibuprofen | Brufen | Ibucine | Ibugesic | Ibumed | Nurofen | Pedea | Rolab-ibuprofen</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Actiflam | Bren | Butafen | Ibu | Ibufen | Ibufil | Ibuflamar | Ibukant | Ibumex | Ibunate | Intafen | Norswel | Novafen | Nurofen | Nurofen for children | Nurofen for children strawberry | Pedifen | Profen | Profundin | Rufen | Rumifen | Sirofen</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dolex | Nurofen | Nurofen express | Nurofen for children</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6731494">
<a name="6731494"></a>Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. <i>Am J Nephrol</i>. 1984;4(1):1-6. doi:10.1159/000166764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6731494/pubmed" id="6731494" target="_blank">6731494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320112">
<a name="26320112"></a>Adler Y, Charron P, Imazio M, et al; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J</i>. 2015;36(42):2921-2964. doi:10.1093/eurheartj/ehv318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26320112/pubmed" id="26320112" target="_blank">26320112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Advil.1">
<a name="Advil.1"></a>Advil (ibuprofen) [prescribing information]. Warren, NJ: GlaxoSmithKline; received December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8759674">
<a name="8759674"></a>Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. <i>Am J Gastroenterol</i>. 1996;91(8):1626-1630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8759674/pubmed" id="8759674" target="_blank">8759674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891025">
<a name="29891025"></a>Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. <i>J Pharm Pharm Sci</i>. 2018;21(1s):29854. doi:10.18433/jpps29854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29891025/pubmed" id="29891025" target="_blank">29891025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS). <i>Principles of Analgesic Use</i>. 7th ed. American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19841966">
<a name="19841966"></a>Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. <i>Pediatr Cardiol</i>. 2010;31(1):40-43. doi:10.1007/s00246-009-9542-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19841966/pubmed" id="19841966" target="_blank">19841966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3115366">
<a name="3115366"></a>Andrejak M, Davion T, Gineston JL, Capron JP. Cross hepatotoxicity between non-steroidal anti-inflammatory drugs. <i>Br Med J (Clin Res Ed)</i>. 1987;295(6591):180-181. doi:10.1136/bmj.295.6591.180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3115366/pubmed" id="3115366" target="_blank">3115366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014 109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3958223">
<a name="3958223"></a>Antal EJ, Wright CE 3rd, Brown BL, Albert KS, Aman LC, Levin NW. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. <i>J Clin Pharmacol</i>. 1986;26(3):184-190. doi:10.1002/j.1552-4604.1986.tb02931.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3958223/pubmed" id="3958223" target="_blank">3958223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Apo-Ibuprofen tablets [product monograph]. Toronto, Ontario, Canada: Apotex Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16813969">
<a name="16813969"></a>Aranda JV, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. <i>Semin Perinatol</i>. 2006;30(3):114-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16813969/pubmed" id="16813969" target="_blank">16813969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9099319">
<a name="9099319"></a>Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. <i>Acta Paediatr</i>. 1997;86(3):289-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9099319/pubmed" id="9099319" target="_blank">9099319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Phil American College of Physicians; 2007:105.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27713809">
<a name="27713809"></a>Bagheri MM, Niknafs P, Sabsevari F, et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. <i>Iran J Pediatr</i>. 2016;26(4):e3975. doi:10.5812/ijp.3975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27713809/pubmed" id="27713809" target="_blank">27713809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32479922">
<a name="32479922"></a>Baker M, Perazella MA. NSAIDs in CKD: are they safe? <i>Am J Kidney Dis</i>. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32479922/pubmed" id="32479922" target="_blank">32479922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25074525">
<a name="25074525"></a>Balint B, Stepic N, Todorovic M, et al. Ibuprofen-induced extensive toxic epidermal necrolysis - a multidisciplinary therapeutic approach in a single case. <i>Blood Transfus</i>. 2014;12(3):438-439. doi:10.2450/2014.0065-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25074525/pubmed" id="25074525" target="_blank">25074525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. <i>Crit Care Med</i>. 2013;41(1):263-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317199">
<a name="30317199"></a>Barry RJ, Zanetto U, Kolli S, Morjaria R. Toxic epidermal necrolysis: the red eye and red herrings in casualty. <i>BMJ Case Rep</i>. 2018;2018:bcr2018225861. doi:10.1136/bcr-2018-225861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30317199/pubmed" id="30317199" target="_blank">30317199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668365">
<a name="15668365"></a>Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. <i>Arch Intern Med</i>. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15668365/pubmed" id="15668365" target="_blank">15668365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16785458">
<a name="16785458"></a>Bellini C, Campone F, Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. <i>CMAJ</i>. 2006; 174(13):1843-1844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16785458/pubmed" id="16785458" target="_blank">16785458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216644">
<a name="2216644"></a>Berde C, Ablin A, Glazer J, et al. American Academy of Pediatrics report of the subcommittee on disease-related pain in childhood cancer. <i>Pediatrics</i>. 1990;86(5, pt 2):818-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2216644/pubmed" id="2216644" target="_blank">2216644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12362012">
<a name="12362012"></a>Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12362012/pubmed" id="12362012" target="_blank">12362012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340. doi:10.1097/BOR.0000000000000054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726390">
<a name="23726390"></a>Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23726390/pubmed" id="23726390" target="_blank">23726390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682313">
<a name="24682313"></a>Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. <i>World J Surg</i>. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24682313/pubmed" id="24682313" target="_blank">24682313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017521">
<a name="19017521"></a>Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2008;52(18):1502-1517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19017521/pubmed" id="19017521" target="_blank">19017521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21705120">
<a name="21705120"></a>Bhave G, Neilson EG. Volume depletion versus dehydration: how understanding the difference can guide therapy. <i>Am J Kidney Dis</i>. 2011;58(2):302-309. doi:10.1053/j.ajkd.2011.02.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21705120/pubmed" id="21705120" target="_blank">21705120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26841325">
<a name="26841325"></a>Blanca-López N, Pérez-Alzate D, Andreu I, et al. Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. <i>Allergy</i>. 2016;71(7):1048-1056. doi:10.1111/all.12855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26841325/pubmed" id="26841325" target="_blank">26841325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31496752">
<a name="31496752"></a>Blanca-López N, Soriano V, Garcia-Martin E, Canto G, Blanca M. NSAID-induced reactions: classification, prevalence, impact, and management strategies. <i>J Asthma Allergy</i>. 2019;12:217-233. doi:10.2147/JAA.S164806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31496752/pubmed" id="31496752" target="_blank">31496752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075. doi:10.1213/ANE.0b013e31828a4b54<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31535715">
<a name="31535715"></a>Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD000400. doi:10.1002/14651858.CD000400.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31535715/pubmed" id="31535715" target="_blank">31535715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-719345">
<a name="719345"></a>Brandstetter RD, Mar DD. Reversible oliguric renal failure associated with ibuprofen treatment. <i>Br Med J</i>. 1978;2(6146):1194-1195. doi:10.1136/bmj.2.6146.1194-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/719345/pubmed" id="719345" target="_blank">719345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12512867">
<a name="12512867"></a>Brix AE. Renal papillary necrosis. <i>Toxicol Pathol</i>. 2002;30(6):672-674. doi:10.1080/01926230290166760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12512867/pubmed" id="12512867" target="_blank">12512867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453549">
<a name="23453549"></a>Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23453549/pubmed" id="23453549" target="_blank">23453549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caldolor.1">
<a name="Caldolor.1"></a>Caldolor (ibuprofen) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caldolor.2">
<a name="Caldolor.2"></a>Caldolor (ibuprofen) [product monograph]. Toronto, Ontario, Canada: Alveda Pharmaceuticals Inc; May 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15037526">
<a name="15037526"></a>Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i>. 2004 Mar;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15037526/pubmed" id="15037526" target="_blank">15037526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11752357">
<a name="11752357"></a>Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. <i>N Engl J Med</i>. 2001;345(25):1809-1817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11752357/pubmed" id="11752357" target="_blank">11752357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11509629">
<a name="11509629"></a>Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. <i>J Immunol</i>. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11509629/pubmed" id="11509629" target="_blank">11509629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chalasani.1">
<a name="Chalasani.1"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;00:1-21. https://doi.org/10.14309/ajg.0000000000001259
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/Chalasani.1/pubmed" id="Chalasani.1" target="_blank">Chalasani.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534006">
<a name="16534006"></a>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. <i>Circulation</i>. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16534006/pubmed" id="16534006" target="_blank">16534006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33238721">
<a name="33238721"></a>Chang RW, Tompkins DM, Cohn SM. Are NSAIDs safe? Assessing the risk-benefit Profile of nonsteroidal anti-inflammatory drug use in postoperative pain management. <i>Am Surg</i>. 2021;87(6):872-879. doi:10.1177/0003134820952834<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33238721/pubmed" id="33238721" target="_blank">33238721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964481">
<a name="11964481"></a>Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. <i>Science</i>. 2002;296(5567):539-541. doi:10.1126/science.1068711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11964481/pubmed" id="11964481" target="_blank">11964481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28760789">
<a name="28760789"></a>Chiappini E, Bortone B, Galli L, de Martino M. Guidelines for the symptomatic management of fever in children: systematic review of the literature and quality appraisal with AGREE II. <i>BMJ Open</i>. 2017;7(7):e015404. doi:10.1136/bmjopen-2016-015404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/28760789/pubmed" id="28760789" target="_blank">28760789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChildrensAdvil.1">
<a name="ChildrensAdvil.1"></a>Children's Advil (ibuprofen) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Consumer Healthcare ULC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChildrensAdvil.2">
<a name="ChildrensAdvil.2"></a>Children's Advil Suspension (ibuprofen) [prescribing information]. Madison, NJ: Pfizer Inc; received September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChildrensAdvil.3">
<a name="ChildrensAdvil.3"></a>Children's Advil Suspension (ibuprofen) [prescribing information]. Warren, NJ: GlaxoSmithKline; received September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945352">
<a name="26945352"></a>Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. <i>Medicine (Baltimore)</i>. 2016b;95(9):e2645. doi:10.1097/MD.0000000000002645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26945352/pubmed" id="26945352" target="_blank">26945352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council [published correction appears in <i>J Pain</i>. 2016;17(4):508-510]. <i>J Pain</i>. 2016a;17(2):131-157. doi: 10.1016/j.jpain.2015.12.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6363936">
<a name="6363936"></a>Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1984;310(9):563-572. doi:10.1056/NEJM198403013100905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6363936/pubmed" id="6363936" target="_blank">6363936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626023">
<a name="9626023"></a>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. <i>Am J Med</i>. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9626023/pubmed" id="9626023" target="_blank">9626023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22089267">
<a name="22089267"></a>Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. <i>Clin Pharmacol Ther</i>. 2012;91(4):590-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/22089267/pubmed" id="22089267" target="_blank">22089267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733305">
<a name="24733305"></a>Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. <i>JAMA Intern Med</i>. 2014;174(6):947-953. doi:10.1001/jamainternmed.2014.946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24733305/pubmed" id="24733305" target="_blank">24733305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9515184">
<a name="9515184"></a>Davies NM. Clinical Pharmacokinetics of Ibuprofen. The First 30 Years. <i>Clin Pharmacokinet</i>. 1998;34(2):101-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9515184/pubmed" id="9515184" target="_blank">9515184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799625">
<a name="29799625"></a>Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: implications of changes in renal function associated with concurrent use. <i>J Clin Pharmacol</i>. 2018;58(11):1443-1451. doi:10.1002/jcph.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29799625/pubmed" id="29799625" target="_blank">29799625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19588326">
<a name="19588326"></a>Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral ibuprofen for acute postoperative pain in adults. <i>Cochrane Database Syst Rev</i>. 2009;(3):CD001548. doi:10.1002/14651858.CD001548.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19588326/pubmed" id="19588326" target="_blank">19588326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11603504">
<a name="11603504"></a>Dionne RA, Berthold CW. Therapeutic Uses of Nonsteroidal Anti-inflammatory Drugs in Dentistry. <i>Crit Rev Oral Biol Med</i>. 2001;12(4):315-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11603504/pubmed" id="11603504" target="_blank">11603504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21834936">
<a name="21834936"></a>Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2011;66(11):1428-1433. doi:10.1111/j.1398-9995.2011.02684.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21834936/pubmed" id="21834936" target="_blank">21834936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991794">
<a name="26991794"></a>Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. <i>Br J Clin Pharmacol</i>. 2016;82(1):238-248. doi:10.1111/bcp.12938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26991794/pubmed" id="26991794" target="_blank">26991794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12162474">
<a name="12162474"></a>Doyle G, Jayawardena S, Ashraf E, et al. Efficacy and Tolerability of Nonprescription Ibuprofen Versus Celecoxib for Dental Pain. <i>J Clin Pharmacol</i>. 2002;42(8):912-919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12162474/pubmed" id="12162474" target="_blank">12162474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22147286">
<a name="22147286"></a>Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2012;97(4):F279-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/22147286/pubmed" id="22147286" target="_blank">22147286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Ann Thorac Surg</i>. 2012;94(5):1761-1781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/FDA.1/pubmed" id="FDA.1" target="_blank">FDA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.1">
<a name="Gaffo.1"></a>Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.1">
<a name="Gal.1"></a>Gal P, Ransom JL, Davis SA. Possible ibuprofen-induced kernicterus in a near-term infant with moderate hyperbilirubinemia. <i>J Pediatr Pharmacol Ther</i>. 2006;11:245-250.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247621">
<a name="25247621"></a>Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. <i>Immunohematology</i>. 2014;30(2):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25247621/pubmed" id="25247621" target="_blank">25247621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2213396">
<a name="2213396"></a>Giannini EH, Brewer EJ, Miller ML, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. <i>J Pediatr</i>. 1990;117(4):645-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2213396/pubmed" id="2213396" target="_blank">2213396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359332">
<a name="18359332"></a>Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. <i>Am J Cardiol</i>. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18359332/pubmed" id="18359332" target="_blank">18359332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15809462">
<a name="15809462"></a>Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. <i>Ann Intern Med</i>. 2005;142(7):506-509. doi:10.7326/0003-4819-142-7-200504050-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15809462/pubmed" id="15809462" target="_blank">15809462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17349452">
<a name="17349452"></a>Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. <i>Am J Med</i>. 2007;120(3):280.e1-7. doi:10.1016/j.amjmed.2006.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17349452/pubmed" id="17349452" target="_blank">17349452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11988250">
<a name="11988250"></a>Gournay V, Savagner C, Thiriez G, et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. <i>Lancet</i>. 2002;359(9316):1486-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11988250/pubmed" id="11988250" target="_blank">11988250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15342612">
<a name="15342612"></a>Gregoire N, Gualano V, Geneteau A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. <i>J Clin Pharmacol</i>. 2004;44(10):1114-1124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15342612/pubmed" id="15342612" target="_blank">15342612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34295789">
<a name="34295789"></a>Gui MZ, Ni M, Yin XD, Zhang T, Li ZL. Ibuprofen induced Stevens-Johnson syndrome and liver injury in children: a case report. <i>Transl Pediatr</i>. 2021;10(6):1737-1742. doi:10.21037/tp-21-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/34295789/pubmed" id="34295789" target="_blank">34295789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23325533">
<a name="23325533"></a>Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. <i>Drug Saf</i>. 2013;36(2):135-144. doi:10.1007/s40264-012-0013-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23325533/pubmed" id="23325533" target="_blank">23325533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30112779">
<a name="30112779"></a>Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: preliminary results from the EPIHAM study. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(11):1174-1181. doi:10.1002/pds.4640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30112779/pubmed" id="30112779" target="_blank">30112779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33093140">
<a name="33093140"></a>Hamrick SEG, Sallmon H, Rose AT, et al. Patent ductus arteriosus of the preterm infant. <i>Pediatrics</i>. 2020;146(5):e20201209. doi:10.1542/peds.2020-1209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33093140/pubmed" id="33093140" target="_blank">33093140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11117655">
<a name="11117655"></a>Hersh EV, Levin LM, Cooper SA, et al. Ibuprofen Liquigel for Oral Surgery Pain. <i>Clin Ther</i>. 2000;22(11):1306-1318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11117655/pubmed" id="11117655" target="_blank">11117655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33795792">
<a name="33795792"></a>Hillier K, Jones K, MacInnis M, Mitra S. Comparison of standard versus high-dose ibuprofen for the treatment of hemodynamically significant patent ductus arteriosus in preterm infants. <i>J Perinatol</i>. 2021;41(5):1142-1148. doi:10.1038/s41372-021-01046-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33795792/pubmed" id="33795792" target="_blank">33795792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18307541">
<a name="18307541"></a>Hirt D, Van Overmeire B, Treluyer JM, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. <i>Br J Clin Pharmacol</i>. 2008;65(5):629-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18307541/pubmed" id="18307541" target="_blank">18307541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18193919">
<a name="18193919"></a>Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18193919/pubmed" id="18193919" target="_blank">18193919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317488">
<a name="30317488"></a>Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. <i>Obes Surg</i>. 2019;29(2):394-400. doi:10.1007/s11695-018-3526-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30317488/pubmed" id="30317488" target="_blank">30317488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15754275">
<a name="15754275"></a>Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>Am J Kidney Dis</i>. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15754275/pubmed" id="15754275" target="_blank">15754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IBU600.1">
<a name="IBU600.1"></a>IBU 600-EZS (ibuprofen) [prescribing information]. Shreveport, LA: Dr. Reddy's Laboratories Louisiana LLC; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glasgow.1">
<a name="Glasgow.1"></a>Ibuprofen [prescribing information]. Glasgow, KY: Amneal Pharmaceuticals; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accord.1">
<a name="Accord.1"></a>Ibuprofen [summary of product characteristics]. Devon, UK: Accord-UK Ltd; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.1">
<a name="Actavis.1"></a>Ibuprofen suspension [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strides.1">
<a name="Strides.1"></a>Ibuprofen tablet [prescribing information]. Columbus, OH: American Health Packaging; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imazio.1">
<a name="Imazio.1"></a>Imazio M. Acute pericarditis: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873705">
<a name="21873705"></a>Imazio M, Brucato A, Cemin R, et al; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. <i>Ann Intern Med</i>. 2011;155(7):409-414. doi:10.7326/0003-4819-155-7-201110040-00359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21873705/pubmed" id="21873705" target="_blank">21873705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23992557">
<a name="23992557"></a>Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. <i>N Engl J Med</i>. 2013;369(16):1522-1528. doi:10.1056/NEJMoa1208536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23992557/pubmed" id="23992557" target="_blank">23992557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InfantsAdvil.1">
<a name="InfantsAdvil.1"></a>Infants' Advil White Grape Concentrated Drops (ibuprofen) [prescribing information]. Madison, NJ: Pfizer Inc; No date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8179987">
<a name="8179987"></a>Jain S. Ibuprofen-induced thrombocytopenia. <i>Br J Clin Pract</i>. 1994;48(1):51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8179987/pubmed" id="8179987" target="_blank">8179987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2279802">
<a name="2279802"></a>Joshi YM, Sovani VB, Joshi VV, et al. Comparative evaluation of the antipyretic efficacy of ibuprofen and paracetamol. <i>Indian Pediatr</i>. 1990;27(8):803-806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2279802/pubmed" id="2279802" target="_blank">2279802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JuniorStrengthAdvil.1">
<a name="JuniorStrengthAdvil.1"></a>Junior Strength Advil (ibuprofen) [prescribing information]. Madison, NJ: Pfizer Inc; No date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JuniorStrengthAdvil.2">
<a name="JuniorStrengthAdvil.2"></a>Junior Strength Advil Chewables (ibuprofen) [prescribing information]. Madison, NJ: Pfizer Inc; No date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447669">
<a name="1447669"></a>Kauffman RE, Nelson MV. Effect of Age on Ibuprofen Pharmacokinetics and Antipyretic Response. <i>J Pediatr</i>. 1992;121(6):969-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/1447669/pubmed" id="1447669" target="_blank">1447669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaunitz.1">
<a name="Kaunitz.1"></a>Kaunitz AM. Abnormal uterine bleeding in nonpregnant reproductive-age patients: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23322307">
<a name="23322307"></a>Kay E, Ben-Shoshan M. Anaphylaxis to ibuprofen in a 12-year-old boy. <i>BMJ Case Rep</i>. 2013;2013:bcr2012007873. doi:10.1136/bcr-2012-007873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23322307/pubmed" id="23322307" target="_blank">23322307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2724096">
<a name="2724096"></a>Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. <i>J Pharm Sci</i>. 1989;78(4):324-327. doi:10.1002/jps.2600780413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2724096/pubmed" id="2724096" target="_blank">2724096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Updated January 2013. Accessed May 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21218015">
<a name="21218015"></a>Kim KN. Treatment of juvenile rheumatoid arthritis. <i>Korean J Pediatr</i>. 2010;53(11):936-941. doi:10.3345/kjp.2010.53.11.936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21218015/pubmed" id="21218015" target="_blank">21218015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27692860">
<a name="27692860"></a>Kim SY, Shin SH, Kim HS, Jung YH, Kim EK, Choi JH. Pulmonary arterial hypertension after ibuprofen treatment for patent ductus arteriosus in very low birth weight infants. <i>J Pediatr</i>. 2016;179:49-53.e1. doi:10.1016/j.jpeds.2016.08.103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27692860/pubmed" id="27692860" target="_blank">27692860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587953">
<a name="24587953"></a>Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24587953/pubmed" id="24587953" target="_blank">24587953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31545385">
<a name="31545385"></a>Klar H, Sotošek N, Šelb J, Košnik M. Selective hypersensitivity to a single nonsteroidal anti-inflammatory drug. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2019;28(3):97-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31545385/pubmed" id="31545385" target="_blank">31545385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Knight.1">
<a name="Knight.1"></a>Knight CL, Deyo RA, Staiger TO, Wipf J. Treatment of acute low back pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17609236">
<a name="17609236"></a>Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. <i>Ann Pharmacother</i>. 2007;41(7):1191-1200. doi:10.1345/aph.1K023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17609236/pubmed" id="17609236" target="_blank">17609236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27567654">
<a name="27567654"></a>Koca T, Akcam M. Ibuprofen induced DRESS syndrome in a child. <i>Indian Pediatr</i>. 2016;53(8):745.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27567654/pubmed" id="27567654" target="_blank">27567654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280110">
<a name="24280110"></a>Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. <i>Am J Med</i>. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24280110/pubmed" id="24280110" target="_blank">24280110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7503838">
<a name="7503838"></a>Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. <i>N Engl J Med</i>. 1995;332(13):848-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7503838/pubmed" id="7503838" target="_blank">7503838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17872492">
<a name="17872492"></a>Konstan MW, Schluchter MD, Xue W, et al. Clinical use of Ibuprofen is associated with slower FEV<sub>1</sub> decline in children with cystic fibrosis. <i>Am J Respir Crit Care Med</i>. 2007;176(11):1084-1089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17872492/pubmed" id="17872492" target="_blank">17872492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30216468">
<a name="30216468"></a>Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. <i>Allergy</i>. 2019;74(1):28-39. doi:10.1111/all.13599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30216468/pubmed" id="30216468" target="_blank">30216468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117484">
<a name="24117484"></a>Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2013;68(10):1219-1232. doi:10.1111/all.12260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24117484/pubmed" id="24117484" target="_blank">24117484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749768">
<a name="25749768"></a>Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? <i>Allergy Asthma Immunol Res</i>. 2015;7(4):312-320. doi:10.4168/aair.2015.7.4.312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25749768/pubmed" id="25749768" target="_blank">25749768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982931">
<a name="17982931"></a>Kucharewicz I, Kemona-Chetnik I, Reduta T, Wierzbicka I, Flisiak R, Bodzenta-Lukaszyk A. Drug rash with eosinophilia and systemic symptoms after ibuprofen intake. <i>J Investig Allergol Clin Immunol</i>. 2007;17(5):347-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17982931/pubmed" id="17982931" target="_blank">17982931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32336479">
<a name="32336479"></a>Kumar A, Gosavi RS, Sundaram V, et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. <i>J Pediatr</i>. 2020;222:79-84.e2. doi:10.1016/j.jpeds.2020.01.058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32336479/pubmed" id="32336479" target="_blank">32336479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12014386">
<a name="12014386"></a>Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. <i>Eur J Pediatr</i>. 2002;161(4):202-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12014386/pubmed" id="12014386" target="_blank">12014386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483309">
<a name="28483309"></a>Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):537-545. doi:10.1016/j.jaip.2016.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/28483309/pubmed" id="28483309" target="_blank">28483309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955443">
<a name="20955443"></a>Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. <i>Aliment Pharmacol Ther</i>. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/20955443/pubmed" id="20955443" target="_blank">20955443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25402512">
<a name="25402512"></a>Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. <i>Ann Intern Med</i>. 2014;161(10):690-698. doi:10.7326/M13-1581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25402512/pubmed" id="25402512" target="_blank">25402512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909103">
<a name="7909103"></a>Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. <i>Lancet</i>. 1994;343(8905):1075-1078. doi:10.1016/s0140-6736(94)90185-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7909103/pubmed" id="7909103" target="_blank">7909103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299844">
<a name="23299844"></a>Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. doi:10.1136/bmj.e8525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23299844/pubmed" id="23299844" target="_blank">23299844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23276438">
<a name="23276438"></a>Lee CH, Chen HN, Tsao LY, et al. Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. <i>Pediatr Neonatol</i>. 2012;53(6):346-353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23276438/pubmed" id="23276438" target="_blank">23276438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30544107">
<a name="30544107"></a>Lee EY, Teitelbaum D, Chiam M, Vadas P. Characterization of patients with ibuprofen hypersensitivity. <i>Int Arch Allergy Immunol</i>. 2019;178(2):177-181. doi:10.1159/000494388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30544107/pubmed" id="30544107" target="_blank">30544107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7884951">
<a name="7884951"></a>Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. <i>JAMA.</i> 1995;273(12):929-933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7884951/pubmed" id="7884951" target="_blank">7884951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10506264">
<a name="10506264"></a>Lesko SM, Mitchell A. The safety of acetaminophen and ibuprofen among children younger than two years old. <i>Pediatrics</i>. 1999;104(4). Available at: <a href="http://www.fda.gov/cder/drug/advisory/codeine.htm" target="_blank">http://www.fda.gov/cder/drug/advisory/codeine.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10506264/pubmed" id="10506264" target="_blank">10506264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LeWinter.1">
<a name="LeWinter.1"></a>LeWinter MM. Pericardial complications of myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11735667">
<a name="11735667"></a>Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. <i>Paediatr Drugs</i>. 2001;3(11):817-858.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11735667/pubmed" id="11735667" target="_blank">11735667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15120056">
<a name="15120056"></a>Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary; The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. <i>Eur Heart J</i>. 2004;25(7):587-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15120056/pubmed" id="15120056" target="_blank">15120056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3533137">
<a name="3533137"></a>Mäkäräinen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. <i>Br J Obstet Gynaecol</i>. 1986;93(9):974-978. doi:10.1111/j.1471-0528.1986.tb08019.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3533137/pubmed" id="3533137" target="_blank">3533137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3689062">
<a name="3689062"></a>Marasco WA, Gikas PW, Azziz-Baumgartner R, Hyzy R, Eldredge CJ, Stross J. Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. <i>Arch Intern Med</i>. 1987;147(12):2107-2116. doi:10.1001/archinte.147.12.2107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3689062/pubmed" id="3689062" target="_blank">3689062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17898664">
<a name="17898664"></a>Marchei E, Pellegrini M, Pichini S, et al. Are False-Positive Phencyclidine Immunoassay Instant-View Multi-Test Results Caused by Overdose Concentrations of Ibuprofen, Metamizol, and Dextromethorphan? <i>Ther Drug Monit.</i> 2007;29(5):671-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17898664/pubmed" id="17898664" target="_blank">17898664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26224322">
<a name="26224322"></a>Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. <i>Cochrane Database Syst Rev</i>. 2015;2015(7):CD001751. doi:10.1002/14651858.CD001751.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26224322/pubmed" id="26224322" target="_blank">26224322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8660083">
<a name="8660083"></a>McIntyre J, Hull D. Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. <i>Arch Dis Child</i>. 1996;74(2):164-167. doi:10.1136/adc.74.2.164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8660083/pubmed" id="8660083" target="_blank">8660083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis. </i>2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23163542">
<a name="23163542"></a>Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of analgesia. <i>Int J Clin Pract Suppl</i>. 2013;(178):3-8. doi:10.1111/ijcp.12053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23163542/pubmed" id="23163542" target="_blank">23163542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22307401">
<a name="22307401"></a>Meißner U, Chakrabarty R, Topf HG, et al. Improved closure of patent ductus arteriosus with high doses of ibuprofen. <i>Pediatr Cardiol</i>. 2012;33(4):586-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/22307401/pubmed" id="22307401" target="_blank">22307401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416889">
<a name="31416889"></a>Mérida E, Praga M. NSAIDs and nephrotic syndrome. <i>Clin J Am Soc Nephrol</i>. 2019;14(9):1280-1282. doi:10.2215/CJN.08090719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31416889/pubmed" id="31416889" target="_blank">31416889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Midol.2017.05">
<a name="Midol.2017.05"></a>Midol liquid gels (ibuprofen) [prescribing information]. Morristown, NJ: Bayer HealthCare LLC; received May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360563">
<a name="23360563"></a>Misurac JM, Knoderer CA, Leiser JD, et al. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23360563/pubmed" id="23360563" target="_blank">23360563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29584842">
<a name="29584842"></a>Mitra S, Florez ID, Tamayo ME, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. <i>JAMA</i>. 2018;319(12):1221-1238. doi:10.1001/jama.2018.1896<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29584842/pubmed" id="29584842" target="_blank">29584842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879670">
<a name="10879670"></a>Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. <i>Clin Nephrol</i>. 2000;53(6):483-485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10879670/pubmed" id="10879670" target="_blank">10879670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Motrin.1">
<a name="Motrin.1"></a>Motrin IB (ibuprofen) [prescribing information]. Fort Washington, PA: Johnson &amp; Johnson Consumer Inc; received March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Motrin.2">
<a name="Motrin.2"></a>Motrin IB (ibuprofen) [prescribing information]. Fort Washington, PA: Johnson &amp; Johnson Consumer Inc; received November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Motrin.3">
<a name="Motrin.3"></a>Motrin (ibuprofen) [prescribing information]. Fort Washington, PA: Johnson &amp; Johnson Consumer Inc; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508. doi:10.2146/ajhp140024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31264694">
<a name="31264694"></a>Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. <i>Nephrol Dial Transplant</i>. 2019;34(7):1145-1154. doi:10.1093/ndt/gfz062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31264694/pubmed" id="31264694" target="_blank">31264694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/NICE.1/pubmed" id="NICE.1" target="_blank">NICE.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neoprofen.1">
<a name="Neoprofen.1"></a>Neoprofen (ibuprofen) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10687453">
<a name="10687453"></a>Nguyen AM, Graham DY, Gage T, et al. Nonsteroidal Anti-inflammatory Drug Use in Dentistry: Gastrointestinal Implications. <i>Gen Dent</i>. 1999;47(6):590-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10687453/pubmed" id="10687453" target="_blank">10687453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nield.1">
<a name="Nield.1"></a>Nield LS, Kamat D. Fever. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 201.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959716">
<a name="27959716"></a>Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. <i>N Engl J Med</i>. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27959716/pubmed" id="27959716" target="_blank">27959716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3045551">
<a name="3045551"></a>Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). <i>N Engl J Med</i>. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3045551/pubmed" id="3045551" target="_blank">3045551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25011346">
<a name="25011346"></a>O'Donnell FT, Rosen KR. Pediatric pain management: a review. <i>Mo Med</i>. 2014;111(3):231-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25011346/pubmed" id="25011346" target="_blank">25011346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633310">
<a name="23633310"></a>Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2013;(4):CD003481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23633310/pubmed" id="23633310" target="_blank">23633310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32045960">
<a name="32045960"></a>Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. <i>Cochrane Database Syst Rev</i>. 2020;2(2):CD003481. doi:10.1002/14651858.CD003481.pub8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32045960/pubmed" id="32045960" target="_blank">32045960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30264852">
<a name="30264852"></a>Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. <i>Cochrane Database Syst Rev</i>. 2018;9(9):CD003481. doi:10.1002/14651858.CD003481.pub7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30264852/pubmed" id="30264852" target="_blank">30264852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11697757">
<a name="11697757"></a>Olson NZ, Otero AM, Marrero I, et al. Onset of Analgesia for Liquigel Ibuprofen 400 mg, Acetaminophen 1000 mg, Ketoprofen 25 mg, and Placebo in the Treatment of Postoperative Dental Pain. <i>J Clin Pharmacol</i>. 2001;41(11):1238-1247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11697757/pubmed" id="11697757" target="_blank">11697757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052268">
<a name="28052268"></a>Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. <i>Digestion</i>. 2017;95(1):22-28. doi:10.1159/000452356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/28052268/pubmed" id="28052268" target="_blank">28052268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18752387">
<a name="18752387"></a>Pai VB, Sakadjian A, Puthoff TD. Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus. <i>Pharmacotherapy</i>. 2008;28(9):1162-1182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18752387/pubmed" id="18752387" target="_blank">18752387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pandharipande.1">
<a name="Pandharipande.1"></a>Pandharipande P, McGrane S. Pain control in the critically ill adult patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469671">
<a name="16469671"></a>Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of <i>Helicobacter pylori</i> and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clin Gastroenterol Hepatol</i>. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16469671/pubmed" id="16469671" target="_blank">16469671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9409050">
<a name="9409050"></a>Pearlman B, Boyatzis S, Daly C, et al. The Analgesic Efficacy of Ibuprofen in Periodontal Surgery: A Multicentre Study. <i>Aust Dent J</i>. 1997;42(5):328-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9409050/pubmed" id="9409050" target="_blank">9409050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Petty.1">
<a name="Petty.1"></a>Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. <i>Textbook of Pediatric Rheumatology</i>. 7th ed. Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012355">
<a name="2012355"></a>Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. <i>Ann Intern Med</i>. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2012355/pubmed" id="2012355" target="_blank">2012355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31166468">
<a name="31166468"></a>Pires SAP, Lemos AP, Pereira EPMN, Maia PADSV, Agro JPSEABD. Ibuprofen-induced aseptic meningitis: a case report. <i>Rev Paul Pediatr</i>. 2019;37(3):382-385. doi:10.1590/1984-0462/;2019;37;3;00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31166468/pubmed" id="31166468" target="_blank">31166468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6420135">
<a name="6420135"></a>Poirier TI. Reversible renal failure associated with ibuprofen: case report and review of the literature. <i>Drug Intell Clin Pharm</i>. 1984;18(1):27-32. doi:10.1177/106002808401800103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6420135/pubmed" id="6420135" target="_blank">6420135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26007314">
<a name="26007314"></a>Pourarian S, Takmil F, Cheriki S, Amoozgar H. The effect of oral high-dose ibuprofen on patent ductus arteriosus closure in preterm infants. <i>Am J Perinatol</i>. 2015;32(12):1158-1163. doi:10.1055/s-0035-1551671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26007314/pubmed" id="26007314" target="_blank">26007314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27322907">
<a name="27322907"></a>Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. <i>Headache</i>. 2016;56(7):1194-1200. doi:10.1111/head.12870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27322907/pubmed" id="27322907" target="_blank">27322907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21127424">
<a name="21127424"></a>Promes JT, Safcsak K, Pavliv L, Voss B, Rock A. A prospective, multicenter, randomized, double-blind trial of IV ibuprofen for treatment of fever and pain in burn patients. <i>J Burn Care Res</i>. 2011;32(1):79-90. doi:10.1097/BCR.0b013e3182037300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21127424/pubmed" id="21127424" target="_blank">21127424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633348">
<a name="23633348"></a>Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. <i>Cochrane Database Syst Rev</i>. 2013;2013(4):CD008039. doi:10.1002/14651858.CD008039.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23633348/pubmed" id="23633348" target="_blank">23633348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439535">
<a name="25439535"></a>Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. <i>Prim Care</i>. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25439535/pubmed" id="25439535" target="_blank">25439535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19949916">
<a name="19949916"></a>Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. <i>Inflammopharmacology</i>. 2009;17(6):275-342. doi:10.1007/s10787-009-0016-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19949916/pubmed" id="19949916" target="_blank">19949916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031832">
<a name="20031832"></a>Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. <i>Circ Cardiovasc Qual Outcomes</i>. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/20031832/pubmed" id="20031832" target="_blank">20031832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24695355">
<a name="24695355"></a>Rigourd V, de Villepin B, Amirouche A, et al. Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 "Antalait" study. <i>Ther Drug Monit</i>. 2014;36(5):590-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24695355/pubmed" id="24695355" target="_blank">24695355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25490169">
<a name="25490169"></a>Roales-Gómez V, Molero AI, Pérez-Amarilla I, et al. DRESS syndrome secondary to ibuprofen as a cause of hyperacute liver failure. <i>Rev Esp Enferm Dig</i>. 2014;106(7):482-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25490169/pubmed" id="25490169" target="_blank">25490169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12358284">
<a name="12358284"></a>Rodríguez-González F, Montero JL, Puente J, et al. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. <i>Am J Gastroenterol</i>. 2002;97(9):2476-2477. doi:10.1111/j.1572-0241.2002.06015.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12358284/pubmed" id="12358284" target="_blank">12358284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18253976">
<a name="18253976"></a>Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD000396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18253976/pubmed" id="18253976" target="_blank">18253976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020251">
<a name="29020251"></a>Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>Eur Heart J</i>. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29020251/pubmed" id="29020251" target="_blank">29020251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33100559">
<a name="33100559"></a>Sahu N, Roy J, Vunnam R, Golamari R, Jain R. Naproxen-induced thrombocytopenia. <i>Proc (Bayl Univ Med Cent)</i>. 2020;33(4):653-654. doi:10.1080/08998280.2020.1798724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33100559/pubmed" id="33100559" target="_blank">33100559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16111447">
<a name="16111447"></a>Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. <i>Expert Opin Drug Saf</i>. 2005;4(5):837-848. doi:10.1517/14740338.4.5.837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16111447/pubmed" id="16111447" target="_blank">16111447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3545733">
<a name="3545733"></a>Sanford-Driscoll M, Knodel LC. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. <i>Drug Intell Clin Pharm</i>. 1986;20(12):925-934. doi:10.1177/106002808602001202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3545733/pubmed" id="3545733" target="_blank">3545733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33528572">
<a name="33528572"></a>Santamaria JA, Cancio LC, Reed D, et al. Complete fusion of both eyelids in Stevens-Johnson Syndrome: case report. <i>J Burn Care Res</i>. 2021;42(5):1023-1025. doi:10.1093/jbcr/irab024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/33528572/pubmed" id="33528572" target="_blank">33528572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269020">
<a name="19269020"></a>Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thromb Res</i>. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19269020/pubmed" id="19269020" target="_blank">19269020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555710">
<a name="21555710"></a>Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i>. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21555710/pubmed" id="21555710" target="_blank">21555710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17005625">
<a name="17005625"></a>Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. <i>Am J Epidemiol</i>. 2006;164(9):881-889. doi:10.1093/aje/kwj331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17005625/pubmed" id="17005625" target="_blank">17005625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-579229">
<a name="579229"></a>Schweitz MC, Nashel DJ, Alepa FP. Ibuprofen in the treatment of acute gouty arthritis. <i>JAMA</i>. 1978;239(1):34-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/579229/pubmed" id="579229" target="_blank">579229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwenk.1">
<a name="Schwenk.1"></a>Schwenk ES. Nonopioid pharmacotherapy for acute pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scott.1">
<a name="Scott.1"></a>Scott CS, Retsch-Bogart GZ, Kustra RP, et al. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. <i>J Pediatr</i>. 1999;134(1):58-63.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7306246">
<a name="7306246"></a>Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. <i>Arthritis Rheum</i>. 1981;24(9):1208-1210. doi:10.1002/art.1780240917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7306246/pubmed" id="7306246" target="_blank">7306246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31993263">
<a name="31993263"></a>Shaikhain TA, Al-Husayni F, Elder K. Ibuprofen-induced anaphylactic shock in adult Saudi patient. <i>Cureus</i>. 2019;11(12):e6425. doi:10.7759/cureus.6425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31993263/pubmed" id="31993263" target="_blank">31993263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-935827">
<a name="935827"></a>Similä S, Kouvalainen K, Keinänen S. Oral antipyretic therapy. <i>Scand J Rheumatol</i>. 1976;5(2):81-83. doi:10.3109/03009747609099895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/935827/pubmed" id="935827" target="_blank">935827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith RP, Kaunitz AM. Dysmenorrhea in adult women: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solomon.1">
<a name="Solomon.1"></a>Solomon DF. NSAIDs: therapeutic use and variability of response in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28756267">
<a name="28756267"></a>Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. <i>Am J Med</i>. 2017 Dec;130(12):1415-1422.e4. doi:10.1016/j.amjmed.2017.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/28756267/pubmed" id="28756267" target="_blank">28756267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837266">
<a name="15837266"></a>Steinhubl SR. The Use of Anti-Inflammatory Analgesics in the Patient With Cardiovascular Disease: What a Pain. <i>J Am Coll Cardiol</i>. 2005;45(8):1302-1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15837266/pubmed" id="15837266" target="_blank">15837266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-276660">
<a name="276660"></a>Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. <i>N Y State J Med</i>. 1978;78(8):1239-1243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/276660/pubmed" id="276660" target="_blank">276660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8379803">
<a name="8379803"></a>Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FE Jr. Nonsteroidal anti-inflammatory drugs and neutropenia.<i> Arch Intern Med</i>. 1993;153(18):2119-2124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8379803/pubmed" id="8379803" target="_blank">8379803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357332">
<a name="21357332"></a>Sullivan JE, Farrar HC; Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. <i>Pediatrics</i>. 2011;127(3):580-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21357332/pubmed" id="21357332" target="_blank">21357332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31937550">
<a name="31937550"></a>Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i>. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31937550/pubmed" id="31937550" target="_blank">31937550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva-Profen.1">
<a name="Teva-Profen.1"></a>Teva-Profen (ibuprofen) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15717178">
<a name="15717178"></a>Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. <i>Eur J Pediatr</i>. 2005;164(3):135-140. doi:10.1007/s00431-004-1596-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15717178/pubmed" id="15717178" target="_blank">15717178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943657">
<a name="26943657"></a>Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. <i>World J Surg</i>. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26943657/pubmed" id="26943657" target="_blank">26943657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6720796">
<a name="6720796"></a>Townsend RJ, Benedetti TJ, Erickson SH, et al. Excretion of ibuprofen into breast milk. <i>Am J Obstet Gynecol</i>. 1984;149(2):184-186. doi:10.1016/0002-9378(84)90195-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6720796/pubmed" id="6720796" target="_blank">6720796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17410098">
<a name="17410098"></a>Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. <i>Kidney Int</i>. 2007;72(4):517-520. doi:10.1038/sj.ki.5002251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17410098/pubmed" id="17410098" target="_blank">17410098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VanOvermeire.1">
<a name="VanOvermeire.1"></a>Van Overmeire B. Common clinical and practical questions on the use of intravenous ibuprofen lysine for the treatment of patent ductus arteriosus. <i>J Pediatr Pharmacol Ther</i>. 2007;12:194-206.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10974130">
<a name="10974130"></a>Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. <i>N Engl J Med. </i>2000;343(10):674-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10974130/pubmed" id="10974130" target="_blank">10974130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12723743">
<a name="12723743"></a>Van Overmeire B. The Use of Ibuprofen in Neonates in the Treatment of Patent Ductus Arteriosus. <i>Int J Clin Pract Suppl</i>. 2003;(135):23-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12723743/pubmed" id="12723743" target="_blank">12723743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11673749">
<a name="11673749"></a>Van Overmeire B, Touw D, Schepens PJ, et al. Ibuprofen Pharmacokinetics in Preterm Infants With Patent Ductus Arteriosus. <i>Clin Pharmacol Ther</i>. 2001;70(4):336-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11673749/pubmed" id="11673749" target="_blank">11673749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1321554">
<a name="1321554"></a>Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. <i>Agents Actions Suppl</i>. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/1321554/pubmed" id="1321554" target="_blank">1321554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9278216">
<a name="9278216"></a>Walter K, Dilger C. Ibuprofen in Human Milk. <i>Br J Clin Pharmacol</i>. 1997;44(2):211-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9278216/pubmed" id="9278216" target="_blank">9278216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10377455">
<a name="10377455"></a>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. <i>Proc Natl Acad Sci U S A</i>. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10377455/pubmed" id="10377455" target="_blank">10377455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7184678">
<a name="7184678"></a>Weibert RT, Townsend RJ, Kaiser DG, Naylor AJ. Lack of ibuprofen secretion into human milk. <i>Clin Pharm</i>. 1982;1(5):457-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7184678/pubmed" id="7184678" target="_blank">7184678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390124">
<a name="10390124"></a>Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i>. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10390124/pubmed" id="10390124" target="_blank">10390124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207919">
<a name="30207919"></a>White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. <i>N Engl J Med</i>. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/30207919/pubmed" id="30207919" target="_blank">30207919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wu.1">
<a name="Wu.1"></a>Wu EY, Egla Rabinovich C. Juvenile idiopathic arthritis. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 180.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15101300">
<a name="15101300"></a>Wynn RL. Update on Nonprescription Pain Relievers for Dental Pain. <i>Gen Dent</i>. 2004;52(2):94-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15101300/pubmed" id="15101300" target="_blank">15101300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667211">
<a name="29667211"></a>Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. <i>Aliment Pharmacol Ther</i>. 2018;47(11):1453-1463. doi:10.1111/apt.14610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/29667211/pubmed" id="29667211" target="_blank">29667211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15009394">
<a name="15009394"></a>Yesudian PD, Penny M, Azurdia RM, King CM. Ibuprofen-induced acute generalized exanthematous pustulosis. <i>Int J Dermatol</i>. 2004;43(3):208-210. doi:10.1111/j.1365-4632.2004.01860.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15009394/pubmed" id="15009394" target="_blank">15009394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35404294">
<a name="35404294"></a>Yeung T, Shahroor M, Jain A, Weisz D, Jasani B. Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. <i>J Neonatal Perinatal Med</i>. 2022;15(3):501-510. doi:10.3233/NPM-210968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/35404294/pubmed" id="35404294" target="_blank">35404294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.1">
<a name="Zeltzer.1"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32317121">
<a name="32317121"></a>Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. <i>Am J Kidney Dis</i>. 2020;76(2):184-193. doi:10.1053/j.ajkd.2019.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/32317121/pubmed" id="32317121" target="_blank">32317121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28516288">
<a name="28516288"></a>Ziesenitz VC, Zutter A, Erb TO, van den Anker JN. Efficacy and safety of ibuprofen in infants aged between 3 and 6 months. <i>Paediatr Drugs</i>. 2017;19(4):277-290. doi:10.1007/s40272-017-0235-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/28516288/pubmed" id="28516288" target="_blank">28516288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-447795">
<a name="447795"></a>Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. <i>J Clin Endocrinol Metab</i>. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/447795/pubmed" id="447795" target="_blank">447795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31984540">
<a name="31984540"></a>Zoubek ME, Lucena MI, Andrade RJ, Stephens C. Systematic review: ibuprofen-induced liver injury. <i>Aliment Pharmacol Ther</i>. 2020;51(6):603-611. doi:10.1111/apt.15645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/31984540/pubmed" id="31984540" target="_blank">31984540</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8547 Version 1048.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
